JPH08502285A - N-arylheteroarylalkyl 1-cycloalkyl-imidazol-2-one compounds for treating cardiovascular disorders - Google Patents

Abstract

(57) Summary A class of N-arylheteroarylalkyl 1-cycloalkyl-imidazol-2-one compounds useful for the treatment of cardiovascular disorders such as hypertension and congestive heart failure has been described. Compounds of particular interest are formulas [Where A is Where R ¹ , R ² and R ³ are each independently hydride, alkyl, alkoxy, halo, hydroxy, carboxyl, alkoxycarbonyl, formyl and acetyl; R ⁷ is hydride; R ⁸ is alkyl R ⁹ is COOH and Which is an acidic group selected from the following)] or an angiotensin II antagonist represented by or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt thereof.

Description

Detailed Description of the Invention N-arylheteroarylalkyl 1-cycloalkyl-imines for the treatment of cardiovascular disorders Dazol-2-one compound                                 Related application   This application is US Patent Application Serial No. 07 / 681,01 filed April 5, 1991. US patent application serial number filed on April 1, 1992, which is a continuation-in-part application of No. 1 No. PCT / US92 / 02439 is a partial continuation application.                                 Field of the invention   Non-pep used to treat cardiovascular disorders such as hypertension and congestive heart failure Described tided N-arylheteroarylalkylimidazol-2-one compounds Has been done. Of particular interest is 1-cycloalkyl-imidazol-2-one 1-Cycloa having an arylheteroarylmethyl group attached to the 3-nitrogen atom of Angiotensin II Antagoni Provided by Luquil-Imidazol-2-one Strike compound.                                 Background of the Invention   The renin-angiotensin system regulates blood pressure / volume homeostasis and hypertension It is one of the hormonal mechanisms involved in the onset of the disease. Renin-Angiotensincus Kade activation begins with renin secretion from the juxtaglomerular apparatus of the kidney and is the primary Formation is completed by the formation of angiotensin II, a biologically active species. This octapeptide, Angi Otensin II is a potent vasoconstrictor and also stimulates aldosterone secretion and Promotion of thorium and fluid retention, inhibition of renin secretion, increased sympathetic nervous system activity, Increased vasopressin secretion, occurrence of positive myocardial inotropic effects and modulation of other hormonal systems Other physiological effects such as knots also occur.   In previous studies, antagonism of angiotensin II at the receptor was renin-un It has been shown to be a viable approach to the inhibition of the gyotensin system, This mediates the action of the renin-angiotensin system by interacting with tissue receptors The central function of octapeptide has been clarified. Known angiotensin II There are several antagonists, but most of them are peptidic. like this Peptide compounds lack their oral bioavailability or their short-acting Persistence limits their use. In addition, commercially available peptide Ngi Otensin II antagonists (eg salaracin) have significant agonist activity Remains, there is a further limit to its therapeutic application.   Non-peptide compounds with properties of angiotensin II antagonists are also known ing. For example, 2-n-butyl-4-chloro-1- (2-chlorobenzyl) imidazole The sodium salt of Zol-5-acetic acid was used in a series of binding experiments, functional assays and in vitro. Specific competitive angiotensin II antagonis as shown in the Bo test Have the activity [P.C.Wong et al.,J.Pharmacol.Exp.Ther.,247(1), 1-7 (1988)]. same Similarly, 2-butyl-4-chloro-1- (2-nitrobenzyl) imidazole-5-acetic acid Sodium salt has been shown in a series of binding experiments, functional assays and in vivo tests Have specific competitive angiotensin II antagonist activity [A.T.Chiu ,Eur.J.Pharmacol.,157, 13-21 (1988)]. 1-benzylimidazole-5-acete Family of acetate derivatives also possesses the properties of competitive angiotensin II antagonists [A.T.Chiu et al.,J.Pharmacol.Exp.Ther.,250(3), 867-874 (1 989)]. Blankey et al., US Pat. No. 4,816,463, useful as antihypertensive agents. A family of 4,5,6,7-tetrahydro-1H-imidazo (4,5-c) -tetrahydr Ro-pyridine derivatives are described, some of which are labeled angiotensin II labels. Antagonizes binding to the rat adrenal receptor preparation, resulting in flattening of unanesthetized rats. It is described to cause a significant decrease in the arterial pressure. January 20, 1988 Published European Patent No. 253,310 specifically mentions biphenylmethyl-substituted imines. Angio is a series of aralkylimidazole compounds, including the family of azoles It is described as an antagonist for the tensin II receptor. 1989 7 European Patent No. 323,841 published on March 12th has four classes of angios Tensin II antagonists, ie biphenylmethylpyrrole, biphenylme Tyrpyrazole, biphenylmethyl-1,2,3-triazole, and compound 3 , 5-Dibutyl-4-[(2'-carboxybiphenyl-4-yl) methyl] -4H-1 , 2,4-triazole containing biphenylmethyl 4-substituted-4H-1,2,4-tri Azole is described. No. 4,880,804 to Carini et al. Family of Phenylmethylbenzimidazole Compounds Causes Hypertension and Congestion Described as an angiotensin II receptor blocker used in the treatment of congenital heart failure. It has been.   Family of compounds with one or two oxo substituents on the triazole ring Are known. For example, a special feature of East Germany announced on August 3, 1983 No. 160,447, 1,2,4-triazoline-5 used as a herbicide -One compounds family, especially 2,4-dihydro-4,5-bis (phenylmethyi) ) -3H-1,2,4-triazol-3-one. 1972 1 Belgian Patent No. 806,146 published on 16th October has a tranquilizer , Compounds with antihypertensive and analgesic activity, 3- (4-m-chlorophenyl-1-pipera Including dinyl) -propyl) -3,4-diethyl-1,2,4-triazolin-5-one A family of triazolinone compounds has been described. February 28, 1963 Belgian Patent No. 631,842, published in A family of 1,2.4-triazolones with anesthetic, sedative and analgesic activity is described Included in this is the 4-N-aralkyl-1,2,4-triazol-5-one compound Contains the class of. European Patent No. 7,1 published on June 15, 1978 No. 80 is 1,2-disubstituted-4-alkyl-1,2,4-triazolidine-3,5-di The ON family has been described and these have a wide variety of activities such as anti-ulcers, bronchi Dilation, antifertilization and cardiovascular related activities such as antihypertensive, antiarrhythmic, inhibition of platelet aggregation and And has smooth muscle activity. Europe published on March 18, 1987 Patent 283,310 describes the treatment of cerebrovascular and ischemic diseases and anoxia. N for protection against¹-Diarylmethyl-N²-Aminoalkyl-diaza-hete B-ring derivatives have been described.                                 Description of the invention   N-substituted arylheteroants useful for the treatment of cardiovascular disorders, especially cardiovascular disorders The class of alkylalkyl 1-cycloalkyl-imidazol-2-one compounds is of formula I {In the formula, Q is a cycloalkyl group having 3 to about 8 carbon atoms in the ring, and Cycloalkyl groups may be unsubstituted or substituted at one or more substitutable positions with a hydride, Alkyl, alkoxy, cyano, halo, hydroxy, nitro, amino, alkyl Amino, carboxyl, alkoxycarbonyl, formyl, oxo, alkyl carbo 1 or 2 or more independently selected from rubonyl and haloalkylcarbonyl Optionally substituted by groups above; R⁷Is hydride, alkyl, halo, halo Selected from alkyl, formyl, carboxyl and alkoxyalkyl; R⁸ Is alkyl, phenyl, phenylalkyl, cycloalkyl and cycloal Selected from a killalkyl; A is [Wherein m is a number selected from 1 to 4 (including 1 and 4), R⁹Is CO OH and An acidic group selected from] and an acidic group-substituted pyridinyl-phenyl group selected from so A compound or its stereoisomer or tautomer, Rui is a pharmaceutically acceptable salt thereof.   Regioisomers of compounds of formula I, especially substitutions at carbon atoms of the imidazole ring Formed by various substitutions at the nitrogen atom of the imidazole ring in the context of These positional isomers are also included as part of the present invention. For naming, in Formula I For the preferred set of compounds of the present invention included, the imidazole ring number The ring system is shown below. In the formula, Q, R⁷, R⁸, M and A are as defined above.   In the above formula I, Q is [Where R¹, R², R³, R^Four, R^FiveAnd R⁶Independently hydrido and archi Ru, alkoxy, cyano, halo, hydroxy, nitro, amino, alkylamino , Carboxyl, alkoxycarbonyl, formyl, alkylcarbonyl and Selected from haloalkylcarbonyl, R¹And R²Further forms oxo with both May be done, R³And R^FourMay further form oxo with each other, R^FiveAnd And R⁶May further form oxo with each other, and d, b and r are each 0 or To 5 (including 1 and 5), and the sum of d + b + r is 0. To 5 (including 1 and 5)].   Examples of the cycloalkyl group included in the Q group include the following groups. In the formula, R¹, R²And R³Are each as defined above.   The compounds of formula I can be used for example in hypertension, congestive heart failure and arteriosclerosis Of various cardiovascular and cardiovascular-related disorders and glaucoma, including various cardiovascular disorders It is thought to be useful for the treatment of other disorders such as These compounds are also adjunct therapeutic agents However, it seems to be useful. For example, compounds of formula I may be It can also be used in combination with diuretics to treat blood pressure. Similarly, Compounds can also be used in conjunction with certain surgical procedures. For example, Compounds can be used to prevent restenosis after angioplasty. The compound of formula I is Acts as an antagonist or blocker of the gyotensin II (AII) receptor It is therapeutically effective in treating cardiovascular disorders. The compounds of formula I are described above. Therapeutically effective or therapeutically effective in the treatment of cardiovascular and cardiovascular disorders It may be a precursor or prodrug for various compounds.   Within Formula I there is a first group of compounds of more interest, which compounds are of Formula II [Where R¹To R⁶Are independently hydrido, methyl, ethyl, n-propyl , Isopropyl, tert-butyl, methoxy, ethoxy, propoxy, isop Ropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, bromo, Hydroxy, nitro, amino, N-methylamino, N, N-dimethylamino, N- Ethylamino, N, N-diethylamino, carboxyl, methoxycarbonyl, Ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R³And R^FourMay further form oxo with each other; R^Five And R⁶May further form oxo with each other; d, b and r are each A number selected from 0 to 5 (including 1 and 5), the sum of d + b + r Is a number selected from 0 to 5 (including 1 and 5); R⁷Is hydrido , Methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trif Selected from luoromethyl, formyl, carboxyl and dimethoxymethyl; R⁸Is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl Ru, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl , Phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclope Methyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, shik Robutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentyl Selected from ethyl, cyclohexylmethyl and cyclohexylethyl; A is , (In the formula, R⁹Is COOH and Is an acidic group selected from) acidic group-substituted pyridinyl-phenyl groups selected from A compound represented by, or a stereoisomer or tautomer thereof, Alternatively, it is a pharmaceutically acceptable salt thereof.   There is a first group of compounds of more interest in Formula II, which compounds are of Formula II I [Where R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, Isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, but Lomo, hydroxy, nitro, amino, N-methylamino, N, N-dimethylamino , N-ethylamino, N, N-diethylamino, carboxyl, methoxycarboni Ru, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and And trifluoromethylcarbonyl; R¹And R²And both May form an oxo; R⁷Is hydrido, methyl, fluoro, chloro, monof Luoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxy R and dimethoxymethyl; R⁸Is methyl, ethyl, n-propyl, Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- Pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, silane Chloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl Rumethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, Cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and Black hex Selected from ruethyl; A is (In the formula, R⁹Is COOH and Is an acidic group selected from) acidic group-substituted pyridinyl-phenyl groups selected from A compound represented by, or a stereoisomer or tautomer thereof, Alternatively, it is a pharmaceutically acceptable salt thereof.   Within the first group of compounds of formula III there is a first class of compounds of further interest. And these compounds have the formula III (a) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl ,I Sopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pe Nil, isopentyl and neopentyl) or a compound thereof It is a stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof.   A family of particular compounds of particular interest in formula III (a) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2-H -Imidazol-2-one; 1- (2-isopropylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclopropyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclopropyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycyclopropyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H -Imidazol-2-one; 1- (2-acetylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclopropyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,3-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [5- [2 (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-isopropyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,3-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5 - [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Isopropyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-3-ethylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,3-diisopropylcyclopropyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-3-isopropylcyclopropyl) -4-butyl-1,3-dihi Doro-3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydr B-3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the first group of compounds of formula III there is a second class of compounds of even greater interest. And these compounds have the formula III (b) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula III (b) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcyclopropyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclopropyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclopropyl),-4-butyl-1,3-dihydro-3-[[ 6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-tert-butylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclopropyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclopropyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycyclopropyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclopropyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclopropyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,3-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-3-methylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ] -2H-imidazol-2-one; 1- (2-oxo-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,3-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-3-ethylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Chi ]]-2H-imidazol-2-one; 1- (2-acetyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,3-diisopropylcyclopropyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-carboxy-3-isopropylcyclopropyl) -4-butyl-1,3-dihi Doro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydr B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[6 - [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the first group of compounds of formula III there is a third class of compounds of even greater interest. And these compounds have the formula III (c) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula III (c) is the combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- I Midazol-2-one; 1- (2-isopropylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,3-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro - 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-3-methylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,3-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-3-ethylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,3-diisopropylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-3-isopropylcyclopropyl) -4-butyl-1,3-dihi Doro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydr B-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the first group of compounds of formula III there is a fourth class of compounds of further interest. And these compounds have the formula III (d) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula III (d) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,3-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-3-methylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Chi ]]-2H-imidazol-2-one; 1- (2-acetyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,3-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-3-ethylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro - 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,3-diisopropylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-3-isopropylcyclopropyl) -4-butyl-1,3-dihi Doro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinini ]] Methyl] -2H-imidazol-2-one; 1-(-2-Acetyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihi Doro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-oxo-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the first group of compounds of formula III there is a fifth class of compounds of further interest. And these compounds have the formula III (e) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula III (e) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazole-2-one: 1- (2-hydroxycyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,3-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-3-methylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,3-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-3-ethylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,3-diisopropylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-3-isopropylcyclopropyl) -4-butyl-1,3-dihi Doro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridini ] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-3-isopropylcyclopropyl) -4-butyl-1.3-dihydr B-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the first group of compounds of formula III there is a sixth class of compounds of further interest. And these compounds have the formula III (f) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula III (f) is the combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- I Midazol-2-one; 1- (2-oxocyclopropyl) -4-butyl-1.3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,3-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-3-methylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,3-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro - 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-3-ethylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,3-diisopropylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-carboxy-3-isopropylcyclopropyl) -4-butyl-1,3-dihi Doro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-3-isopropylcyclopropyl) -4-butyl-1,3-dihydr B-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Among the compounds of formula II, there is a first group of compounds of more interest, which compounds Thing is formula IV [Where R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, Isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, but Lomo, hydroxy, nitro, amino, N-methylamino, N, N-dimethylamino , N-ethylamino, N, N-diethylamino, carboxyl, methoxycarboni Ru, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and And trifluoromethylcarbonyl; R¹And R²And both May form an oxo; R⁷Is hydrido, methyl, fluoro, chloro, monof Luoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxy R and dimethoxymethyl; R⁸Is methyl, ethyl, n-propyl, Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- Pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, silane Chloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl Rumethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, Cyclopen Tylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexyl Selected from ruethyl; A is (R⁹Is COOH and Is an acidic group selected from) acidic group-substituted pyridinyl-phenyl groups selected from A compound represented by, or a stereoisomer or tautomer thereof, Alternatively, it is a pharmaceutically acceptable salt thereof.   Within the second group of compounds of formula IV there is a first class of compounds of even greater interest , These compounds have the formula IV (a) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo To May be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl, Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- Selected from pentyl, isopentyl and neopentyl) or Is a stereoisomer or tautomer of or a pharmaceutically acceptable salt thereof.   A family of particular compounds of particular interest in formula IV (a) is the compounds of the following groups: And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclobutyl) -4-butyl-1,3-dihydro-2-[[5- [2- ( 1H-tetrazol-5-yl) phenyl],-2-pyridinyl] methyl] -2H-i Midazol-2-one; 1- (2-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [2- ( 1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-propylcyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-isopropylcyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-tert-butylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methoxycyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-hydroxycyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-carboxycyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [ Two -(1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-i Midazol-2-one; 1- (2-acetylcyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-oxocyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [2- ( 1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2,4-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2-H-imidazol-2-one; 1- (2-carboxy-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-acetyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2,4-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-acetyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-ethyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,4-diisopropylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-carboxy-4-isopropylcyclobutyl) -4-butyl-1,3-dihydr B-3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Me Cyl] -2H-imidazol-2-one; 1- (2-oxo-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the second group of compounds of formula IV there is a second class of compounds of even greater interest. , These compounds have the formula IV (b) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula IV (b) is the compounds of the following groups: And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-propylcyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-isopropylcyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methoxycyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-hydroxycyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-carboxycyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-acetylcyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-oxocyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Dazo Two-on; 1- (2,4-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-acetyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2,4-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro- 3 [[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-acetyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-3-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-Ethyl-3-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,4-diisopropylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-carboxy-4-isopropylcyclobutyl) -4-butyl-1,3-dihydr B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-oxo-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the second group of compounds of formula IV there is a third class of compounds of even greater interest. , These compounds have the formula IV (c) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula IV (c), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3-( 1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- ( 1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-propylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-isopropylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methoxycyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-hydroxycyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-carboxycyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-acetylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-oxocyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- ( 1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2,4-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-acetyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2,4-Jetylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1-(-2-isopropyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-acetyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- Two H-imidazol-2-one; 1-(-2-methyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-ethyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [3 (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,4-diisopropylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-carboxy-4-isopropylcyclobutyl) -4-butyl-1,3-dihydr B-3 [[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-oxo-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the second group of compounds of formula IV there is a fourth class of more interesting compounds , These compounds have the formula IV (d) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodobromo, carboxyl, formyl, methylcarbonyl and Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula IV (d), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-propylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-isopropylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methoxycyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-hydroxycyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-carboxycyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1-(-2-acetylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4 -(1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-oxocyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2,4-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ] -2H-imidazol-2-one; 1- (2-acetyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2,4-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-acetyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-ethyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- Three -[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2,4-diisopropylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-carboxy-4-isopropylcyclobutyl) -4-butyl-1,3-dihydr B-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-oxo-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one.   Within the second group of compounds of formula IV there is a fifth class of more interesting compounds ， These compounds have the formula IV (e) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷It is a hydride; R⁸Methyl, ethyl, n-propyl, a Sopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- Selected from pentyl, isopentyl and neopentyl) or Is a stereoisomer or tautomer of or a pharmaceutically acceptable salt thereof.   A family of particular compounds of particular interest in formula IV (e) is the compounds of the following groups: And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3-( 1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- ( 1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-propylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-isopropylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methoxycyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-hydroxycyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [ Three -(1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-i Midazol-2-one; 1- (2-carboxycyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-acetylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-oxocyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- ( 1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2,4-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-acetyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2,4-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Isopropyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-acetyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-ethyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,4-diisopropylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-carboxy-4-isopropylcyclobutyl) -4-butyl-1,3-dihydr B-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl ] Me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-oxo-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one.   Within the second group of compounds of formula IV there is a sixth class of compounds of further interest ， These compounds have the formula IV (f) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula IV (f), a family of particular compounds of particular interest are compounds of the following groups: And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-Bropylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-isopropylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methoxycyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-hydroxycyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-carboxycyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-acetylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Mi Dazol-2-one; 1- (2-oxocyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2,4-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-acetyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2,4-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro- Three -[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-acetyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-ethyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,4-diisopropylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-carboxy-4-isopropylcyclobutyl) -4-butyl-1,3-dihydr B-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-oxo-4-isopropylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Among the compounds of formula II there is a third group of compounds of greater interest, which compounds Thing is formula V [Where R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, Isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, but Lomo, hydroxy, nitro, amino, N-methylamino, N, N-dimethylamino , N-ethylamino, N, N-diethylamino, carboxyl, methoxycarboni Ru, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and And trifluoromethylcarbonyl; R¹And R²And both May form an oxo; R⁷Is hydrido, methyl, fluoro, chloro, monof Luoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxy R and dimethoxymethyl; R⁸Is methyl, ethyl, n-propyl, Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- Pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, silane Chloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl Rumethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, Cyclopen Tylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexyl Selected from ruethyl; A is (R⁹Is COOH and Is an acidic group selected from) acidic group-substituted pyridinyl-phenyl groups selected from A compound represented by, or a stereoisomer or tautomer thereof, Alternatively, it is a pharmaceutically acceptable salt thereof.   Within the third group of compounds of formula V there is a first class of more interesting compounds , These compounds have formula V (a) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo To May be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl, Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- Pentyl. Selected from isopentyl and neopentyl) or Is a stereoisomer or tautomer of or a pharmaceutically acceptable salt thereof.   In formula V (a), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclopentyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclopentyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclopentyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclopentyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclopentyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclopentyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclopentyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-methylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,5-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-ethylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,5-diisopropylcyclopentyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-5-isopropylcyclopentyl) -4-butyl-1,3-dihi Doro-3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydr B-3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl ] Me Cyl] -2H-imidazol-2-one; 1- (2-oxo-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the third group of compounds of formula V there is a second class of more interesting compounds , These compounds have formula V (b) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula V (b), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-Tetrazole-5-l) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-isopropylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Mi Dazol-2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-methylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,5-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-ethylcyclopentyl) -4-butyl-1,3-dihydro- Three -[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-acetyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,5-diisopropylcyclopentyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-carboxy-5-isopropylcyclopentyl) -4-butyl-1,3-dihi Doro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydr B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the third group of compounds of Formula V there is a third class of compounds of even greater interest. , These compounds have formula V (c) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula V (c), the family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclopentyl) -4-butyl-1.3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [ Three -(1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-i Midazol-2-one: 1- (2-isopropylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one: 1- (2-Ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-methylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3 -[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,5-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-ethylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-imidazol-2-one; 1- (2-methyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,5-diisopropylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-5-isopropylcyclopentyl) -4-butyl-1,3-dihi Doro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydr B-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the third group of compounds of Formula V there is a fourth class of more interesting compounds , These compounds have the formula V (d) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula V (d), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-Isopropyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-methylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Chi ]]-2H-imidazol-2-one; 1- (2-acetyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,5-Jetylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Isopropyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-ethylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro - 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,5-diisopropylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-5-isopropylcyclopentyl) -4-butyl-1,3-dihi Doro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydr B-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- It is a group of 2H-imidazol-2-ones.   Within the third group of compounds of Formula V there is a fifth class of more interesting compounds , These compounds have the formula V (e) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula V (e), a family of particular compounds of particular interest are compounds of the following groups: And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-methylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,5-diethylcyclopentyl) -4-butyl-1,3dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-ethylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1-(-2-methyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydr B-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,5-diisopropylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-5-isopropylcyclopentyl) -4-butyl-1,3-dihi Doro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridini ] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydr B-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the third group of compounds of formula V there is a sixth class of compounds of further interest , These compounds have the formula V (f) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula V (f), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- I Midazol-2-one; 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-methylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,5-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro - 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-5-ethylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,5-diisopropylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-carboxy-5-isopropylcyclopentyl) -4-butyl-1,3-dihi Doro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydr B-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methylni-2H-imidazol-2-one; 1- (2,2-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Among the compounds of formula II there is a more interesting fourth group of compounds, the combination of these Thing is formula VI [Where R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, Isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, but Lomo, hydroxy, nitro, amino, N-methylamino, N, N-dimethylamino , N-ethylamino, N, N-diethylamino, carboxyl, methoxycarboni Ru, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and And trifluoromethylcarbonyl; R¹And R²And both May form an oxo; R⁷Is hydrido, methyl, fluoro, chloro, monof Luoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxy R and dimethoxymethyl; R⁸Is methyl, ethyl, n-propyl, Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- Pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, silane Chloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl Rumethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, Cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and Black hex Selected from ruethyl; A is (In the formula, R⁹Is COOH and Is an acidic group selected from) acidic group-substituted pyridinyl-phenyl groups selected from A compound represented by, or a stereoisomer or tautomer thereof, Alternatively, it is a pharmaceutically acceptable salt thereof.   Within the fourth group of compounds of formula VI there is a first class of more interesting compounds , These compounds have the formula VI (a) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl ,I Sopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pe Nil, isopentyl and neopentyl) or a compound thereof It is a stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof.   In formula VI (a), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclohexyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclohexyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclohexyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H -Imidazol-2-one; 1- (2-acetylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,6-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-methylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,6-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5 - [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-6-ethylcyclohexyl) -4-butyl 1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-6-ethylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,6-diisopropylcyclohexyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-6-isopropylcyclohexyl) -4-butyl-1,3-dihi Doro-3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-isopropyl cyclohexyl) -4-butyl-1,3-dihydride B-3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fourth group of compounds of formula VI there is a second class of more interesting compounds , These compounds have the formula VI (b) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula VI (b), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,6-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-methylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,6-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-ethylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Chi ]]-2H-imidazol-2-one; 1- (2-acetyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,6-diisopropylcyclohexyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-carboxy-6-isopropylcyclohexyl) -4-butyl-1,3-dihi Doro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydr B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6 - [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fourth group of compounds of formula VI there is a third class of more interesting compounds , These compounds have the formula VI (c) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula VI (c), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- I Midazol-2-one; 1- (2-isopropylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,6-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro - 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-6-methylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,6-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-ethylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,6-diisopropylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-6-isopropylcyclohexyl) -4-butyl-1,3-dihi Doro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydr B-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fourth group of compounds of formula VI there is a fourth class of more interesting compounds , These compounds have formula VI (d) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula VI (d), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,6-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-methylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Chi ]]-2H-imidazol-2-one; 1- (2-acetyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,6-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-ethylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro - 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,6-diisopropylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [4 (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-carboxy-6-isopropylcyclohexyl) -4-butyl-1,3-dihi Doro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydr B-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fourth group of compounds of formula VI there is a fifth class of more interesting compounds , These compounds have formula VI (e) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula VI (e), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclohexyl) -4-butyl-1,3-dihydro-3 [[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,6-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-methylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,6-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-ethylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4-3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,6-diisopropylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [3 (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-carboxy-6-isopropylcyclohexyl) -4-butyl-1,3-dihi Doro-3-[[4- [3 (1H-tetrazol-5-yl) phenyl] -4-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydr B-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fourth group of compounds of Formula VI there is a sixth class of more interesting compounds , These compounds have the formula VI (f) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula VI (f), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- I Midazol-2-one; 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,6-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-methylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,6-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro - 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-6-ethylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,6-diisopropylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-carboxy-6-isopropylcyclohexyl) -4-butyl-1,3-dihi Doro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-isopropylcyclohexyl) -4-butyl-1,3-dihydr B-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Among the compounds of formula II there is a more interesting fifth group of compounds, the combination of these Thing is formula VI [Where R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, Isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, but Lomo, hydroxy, nitro, amino, N-methylamino, N, N-dimethylamino , N-ethylamino, N, N-diethylamino, carboxyl, methoxycarboni Ru, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and And trifluoromethylcarbonyl; R¹And R²And both May form an oxo; R⁷Is hydrido, methyl, fluoro, chloro, monof Luoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxy R and dimethoxymethyl; R⁸Is methyl, ethyl, n-propyl, Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- Pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, silane Chloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl Rumethyl, cyclopropyl ethyl, cyclobutyl methyl, cyclobutyl ethyl, Cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and Black hex Selected from ruethyl; A is (In the formula, R⁸Is COOH and Is an acidic group selected from) acidic group-substituted pyridinyl-phenyl groups selected from A compound represented by, or a stereoisomer or tautomer thereof, Alternatively, it is a pharmaceutically acceptable salt thereof.   Within the fifth group of compounds of Formula VII there is a first class of more interesting compounds. And these compounds have the formula VII (a) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl ,I Sopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pe Nil, isopentyl and neopentyl) or a compound thereof It is a stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof.   A family of particular compounds of particular interest in formula VII (a) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycycloheptyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycycloheptyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycycloheptyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H -Imidazol-2-one; 1- (2-acetylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocycloheptyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,7-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-methylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,7-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5 - [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl [-2 H-imidazol-2-one; 1- (2-isopropyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-ethylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,7-diisopropylcycloheptyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-7-isopropylcycloheptyl) -4-butyl-1,3-dihi Doro-3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydr B-3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fifth group of compounds of Formula VII there is a second class of compounds of even greater interest. And these compounds have the formula VII (b) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-bropyr , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VII (b) is the combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcycloheptyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcycloheptyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcycloheptyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycycloheptyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycycloheptyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycycloheptyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcycloheptyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocycloheptyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,7-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-methylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,7-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-ethylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Chi ]]-2H-imidazol-2-one; 1- (2-acetyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,7-diisopropylcycloheptyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-carboxy-7-isopropylcycloheptyl) -4-butyl-1,3-dihi Doro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydr B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[6 - [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fifth group of compounds of Formula VII there is a third class of compounds of even greater interest. And these compounds have the formula VII (c) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-bropyr , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VII (c) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2-propylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- I Midazol-2-one; 1- (2-isopropylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,7-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro - 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-7-methylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,7-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-ethylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,7-diisopropylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-7-isopropylcycloheptyl) -4-butyl-1,3-dihi Doro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydr B-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fifth group of compounds of Formula VII there is a fourth class of compounds of further interest. And these compounds have the formula VII (d) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil. Isopropyl. tert-butyl, hydroxy, methoxy, fluoro, Chloro. Iodine. Bromo. Carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VII (d) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl "methyl" -2H-I Midazol-2-one; 1- (2-ethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,7-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-methylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Chi ]]-2H-imidazol-2-one; 1- (2-acetyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,7-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-ethylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro - 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,7-diisopropylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-7-isopropylcycloheptyl) -4-butyl-1,3-dihi Doro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydr B-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fifth group of compounds of Formula VII there is a fifth class of more interesting compounds. And these compounds have the formula VII (e) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VII (e) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one: 1- (2-ethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4pyridinyl] methyl] -2H -Imidazol-2-one; 1- (2-acetylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,7-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-methylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,7-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-ethylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,7-diisopropylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-7-isopropylcycloheptyl) -4-butyl-1,3-dihi Doro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridini ] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydr B-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) senyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fifth group of compounds of Formula VII there is a sixth class of compounds of further interest. And these compounds have the formula VII (f) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VII (f) is a combination of the following groups: Stuff And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-methylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4-[-2 -(1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,7-dimethylcycloheptyl) -4-butyl-1,3-didro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-methylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,7-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-7-ethylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,7-diisopropylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-carboxy-7-isopropylcycloheptyl) -4-butyl-1,3-dihi Doro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-7-isopropylcycloheptyl) -4-butyl-1,3-dihydr B-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 - [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Among the compounds of formula II there is a more interesting sixth group of compounds which Thing is of formula VIII [Where R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, Isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, but Lomo, hydroxy, nitro, amino, N-methylamino, N, N-dimethylamino , N-ethylamino, N, N-diethylamino, carboxyl, methoxycarboni Ru, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and And trifluoromethylcarbonyl; R¹And R²And both May form an oxo; R⁷Is hydrido, methyl, fluoro, chloro, monof Luoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxy R and dimethoxymethyl; R⁸Is methyl, ethyl, n-propyl, Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- Pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, silane Chloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl Rumethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, Cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and Selected from chlorhexylethyl; A is (In the formula, R⁹Is COOH and Is an acidic group selected from) acidic group-substituted pyridinyl-phenyl groups selected from A compound represented by, or a stereoisomer or tautomer thereof, Alternatively, it is a pharmaceutically acceptable salt.   Within the sixth group of compounds of formula VIII there is a first class of compounds of even greater interest. And these compounds have the formula VIII (a) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-bropyr , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VIII (a) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcyclooctyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclooctyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclooctyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclooctyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclooctyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclooctyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclooctyl) -4-butyl-1,3-dihydro-3-[[5- [ 2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- I Midazol-2-one; 1- (2-oxocyclooctyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,8-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3- [5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-methylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,8-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro - 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-8-ethylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,8-diisopropylcyclooctyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-8-isopropylcyclooctyl) -4-butyl-1,3-dihi Doro-3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydride B-3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-8-isopropylcyclooctyl) -4-butyl-, 3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the sixth group of compounds of formula VIII there is a second class of more interesting compounds. And these compounds have the formula VIII (b) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VIII (b) is the combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcyclooctyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclooctyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclooctyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclooctyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclooctyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycyclooctyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclooctyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclooctyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,8-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-methylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-imidazol-2-one: 1- (2-methyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,8-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-ethylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ] -2H-imidazol-2-one; 1- (2-oxo-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,8-diisopropylcyclooctyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-carboxy-8-isopropylcyclooctyl) -4-butyl-1,3-dihi Doro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydride B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the sixth group of compounds of Formula VIII there is a third class of compounds of even greater interest. , These compounds have the formula VIII (c) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VIII (c) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazo 1- (2-ethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H -Imidazol-2-one; 1- (2-tert-butylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,8-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-methylcyclooctyl) -4-butyl-1,3-dihydro- Three -[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-acetyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,8-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-ethylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,8-diisopropylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-8-isopropylcyclooctyl) -4-butyl-1,3-dihi Doro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydride B-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the sixth group of compounds of formula VIII there is a fourth class of more interesting compounds. And these compounds have the formula VIII (d) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VIII (d) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [ 4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,8-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-methylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-imidazol-2-one; 1- (2-methyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,8-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-ethylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,8-diisopropylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-8-isopropylcyclooctyl) -4-butyl-1,3-dihi Do B-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydride B-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3- [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the sixth group of compounds of formula VIII there is a fifth class of more interesting compounds. And these compounds have the formula VIII (e) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is that It is a stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof.   A family of particular compounds of particular interest in formula VIII (e) is the combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [ 3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [ Three -(1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-i Midazol-2-one; 1- (2-oxocyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,8-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-methylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,8-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-ethylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,8-diisopropylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-carboxy-8-isopropylcyclooctyl) -4-butyl-1,3-dihi Doro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydride B-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Me Cyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the sixth group of compounds of formula VIII there is a sixth class of more interesting compounds. And these compounds have the formula VIII (f) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VIII (f) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-methylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-ethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-propylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-isopropylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-tert-butylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methoxycyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-hydroxycyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Carboxycyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-acetylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxocyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,8-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H -Imidazol-2-one; 1- (2-ethyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-methylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,8-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-ethylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,8-diisopropylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-carboxy-8-isopropylcyclooctyl) -4-butyl-1,3-dihi Doro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-8-isopropylcyclooctyl) -4-butyl-1,3-dihydride B-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-8-isopropylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   The term "hydride" means a single hydrogen atom (H). This hydrido group is For example, it binds to an oxygen atom to form a hydroxyl group, and in another example, a single hydroxyl group. When the dolido group is attached to a carbon atom, it forms a> CH-group, and in another example it contains two hydroxy groups. When the dolido group is bonded to a carbon atom, it forms a -CH2- group. The word "alkyl" is simple Used alone or in other terms, such as "haloalkyl," The term "le" includes from 1 to about 20 carbon atoms, preferably from 1 to about 12 carbon atoms. A straight-chain or branched-chain group having a child is included. More preferred alkyl group Is a "lower alkyl" group having from 1 to about 10 carbon atoms. Most preferred Preferred are lower alkyl groups having 1 to about 5 carbon atoms. "Shi The term "chloroalkyl" refers to 3 to about 10 ring atoms, preferably 3 to about Cyclic groups having up to 6 carbon atoms, such as cyclopropyl, cyclobutyl, Includes cyclopentyl and cyclohexyl. The term "haloalkyl" means 1 One or more than one halo group with one or more arbitrary alkyl carbon atoms, preferably Preferably, it includes a group substituted with a group selected from bromo, chloro and fluoro. Including. The term "haloalkyl" refers specifically to monohaloalkyl, dihaloalkyl And polyhaloalkyl groups. A monohaloalkyl group is, for example, It has one of bromine, chlorine or fluorine in the group. Dihaloalkyl and The polyhaloalkyl group may be substituted with two or more identical halo groups, and It may have a combination of different halo groups. A dihaloalkyl group is, for example, a dihaloalkyl group. Two fluorine atoms or di, such as fluoromethyl and difluorobutyl groups 2 chlorine atoms like chloromethyl group, or like fluorochloromethyl It may have one fluorine atom and one chlorine atom. Examples of polyhaloalkyl Include trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluor Rhoethyl, perfluoroethyl and 2,2,3,3-tetrafluoropropyl There is a group. The term "difluoroalkyl" refers to any one or two alkyl It includes an alkyl group having two fluorine atoms substituted on the base carbon atom. " The terms "alkoxy" and "alkoxyalkyl" each refer to 1 to about 10 A linear or branched oxy-containing group having an alkyl portion of up to Include. An example of alkoxy is methoxy. The term "alkoxyalkyl" means Also, alkyl Alkyl groups having two or more alkoxy groups attached to the radical, ie monoalco Includes groups that have formed xyalkyl and dialkoxyalkyl. "Arukoki “Si” or “alkoxyalkyl” groups may further include one or more halo atoms. Substituted by, for example, fluorine, chlorine or bromine, A cooxyalkyl group may be provided. Of "benzyl" and "phenylmethyl" The words have the same meaning. For all the groups defined above, one is the preferred group Is a group containing about 10 carbon atoms.   Specific examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl , N-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, a There are sopentyl, methylbutyl, dimethylbutyl and neopentyl.   Compounds of formula 1 were shown to inhibit angiotensin II activity in mammals. It has been made clear. Angiotensin II is a potent vasoconstrictor and also in mammals Is involved in the formation of aldosterone, which regulates sodium and water balance in rats The Therefore, a compound of formula I may be administered in a hypertensive patient in a therapeutically effective amount. It is therapeutically useful in the treatment of hypertension by administration to This Seki The term “hypertensive patient” as used in the series refers to the prevention or control of hypertension. Otherwise, hypertension develops or suffers from the effects of hypertension or hypertension Means a mammalian animal subject to pressure conditions.   Further within the family of compounds of formula I are their diastereomers and those Included are isomers including pharmaceutically acceptable salts of. "Pharmaceutically acceptable salt" To form alkali metal and addition salts of the free acid or free base Includes salts commonly used in. The nature of the salt makes it pharmaceutically acceptable There is no limit. Suitable pharmaceutically acceptable acid addition salts of compounds of formula I are inorganic acids or It can also be produced from organic acids. Examples of such inorganic acids include hydrochloric acid and bromide. There are hydrous acid, hydroiodic acid, nitric acid, carbonic acid, sulfuric acid and phosphoric acid. Suitable organic acids are Aliphatic, alicyclic, aromatic, aliphatic aromatic, heterocyclic carboxylic acids and sulfonic acids It is selected from a class of organic acids, examples of which are formic acid, acetic acid, propionic acid and amber. Acid, glycolic acid, gluconic acid, lactic acid, malic acid, tartaric acid, citric acid, ascor Binic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid , Glutamic acid, benzoic acid, anthranilic acid, p-hydroxybenzoic acid, salicyl Acid, phenylacetic acid, mandelic acid, emboic acid (pamoeic acid), methanesulfonic acid, Tansulphonic acid, 2-hydroxyethanesulphonic acid, pantothenic acid, benzene Rufonic acid, toluenesulfonic acid, sulfanilic acid, mesylic acid, cyclohexyl acid Minosulfonic acid, stearic acid, alginic acid, β-hydroxybutyric acid, malonic acid, There are galacturic acid and galacturonic acid. Suitable pharmaceutically acceptable compounds of formula I The base addition salts to be contained include aluminum, calcium, lithium and magnesium. , A metal salt made from potassium, sodium and zinc, as well as N, N'-gibe Benzyl ethylenediamine, chloroprocaine, choline, diethanolamine, d Made from Tilenediamine, Meglumine (N-Methylglucamine) and Procaine The organic salts formed are included. All these salts are customary from compounds corresponding to formula I By means of, for example, reacting a suitable acid or base with a compound of formula I Can be manufactured.                               General composition operation   The compounds of the present invention can be synthesized according to the procedures of Reaction Schemes I to XXXI below. Wear. In the reaction scheme, the R substituents are the same as for the above formula I unless otherwise noted. As defined.                                 Reaction Diagram I   Synthetic Reaction Diagram I: Boric acid1(In this case, R⁹Is N-tert-butyl-N-methyl Carboxamide). In step 1, benzoic acid Treatment with onyl yields the corresponding acid chloride, which is then N-tert-butyl-N- Reaction with methylamine gives N-tert-butyl-N-methylbenzamide. In step 2, the amide is ortho-metallated and then trimethylborate is added. React. Free boric acid when hydrolyzed1Generates.                                 Reaction diagram II   Synthetic reaction diagram II shows boric acid1(In this case, R⁹Is N-triphenylmethyl-1H-te Is a trazole). In step 1, 2-bromobenzonitri Corresponding tetrazole by reacting Aldrich with tributyltin azide To get. In step 2, this tetrazole was added in the presence of triethylamine. Protected bromophenyltetrazole by reacting with Riphenylmethyl chloride Get In step 3, by halogen-metal exchange with n-butyllithium To produce the corresponding ortholithium species, which is reacted with trimethylborate The Free boric acid1Is produced by hydrolysis.                               Reaction Diagram III   Synthesis Scheme III shows the corresponding N-Boc-amino acidThreeFrom N-Boc-ketone2 (Or R⁷= H indicates production of aldehyde). In step 1, amino acidThreeWas added with chloroformic acid isobutyl ester in the presence of triethylamine. And react with N, O-dimethylhydroxylamine to give the corresponding N-methoxy- N-methylamideFourTo get. In step 2, amideFourThe organolithium reagent R⁷-Li [or R⁷= H, lithium aluminum hydride (LAH)] Reaction with the desired ketone2(Or R⁷= H, an aldehyde) is obtained.                                 Reaction Diagram IV Method A:   Figure IV shows the corresponding amide.FourImidazole-2-O by Method A from The5Shows the production of. In step 1, the protected amideFour(Scheme III Smell Produced by reacting with trifluoroacetic acid (TFA)6To obtain. In step 2, salt6The appropriate isocyanate in the presence of triethylamine. Out7Reacted with urea8To get. In step 3, urea8Organic lithium trial Medicine R⁷-Li [or R⁷= H, lithium aluminum hydride (LAH) ], And then treated with dilute acid during the post-treatment procedure to react with imidazol-2-one5To Cyclize.                                 Reaction diagram V Method B:   Synthetic Reaction Scheme V, Corresponding N-Boc-protected aminoketone2(R⁷= H Is an aldehyde) and imidazol-2-one by method B5Shows the production of. Work In step 1, a carbonyl compound2Dioxane (prepared in Reaction Scheme III) Hydrochloride with anhydrous hydrogen chloride in9To get. In step 2, salt9Chloro Suitable isocyanate in form7Reacted with imidazol-2-one5Get directly The                                 Reaction Diagram VI Method C:   Synthetic Reaction Scheme VI shows the corresponding N-Boc-protected aminoketone2(R⁷= H Aldehyde) to imidazol-2-one by Method C5Shows the production of. In step 1, a carbonyl compound2(Produced in Reaction Scheme III) Cyclic ketal by reaction with methyl-1,3-propanediol10To get. Process In 2, ketal10Reacts with TFA to give the free amine TFA salt11Got The In step 3, salt11The appropriate isocyanate in the presence of triethylamine. Out7React with urea ketal12To get. In step 4, urine ketal12 Was reacted with 6N hydrochloric acid at 60 ° C to give the desired imidazol-2-one5Get directly ．                           Reaction Diagram VII   Synthetic Reaction Scheme VII shows 2-bromomethyl- from 2-picoline (Aldrich). 5-bromopyridine (13) And 5-bromo-2-pyridinecarboxaldehyde (1 Four ) Production. In step 1, 2-picoline was added at high temperature to a large excess of al chloride. 5-Bromo-2-picoline (reacted with bromine in the presence of minium15) Is obtained. In step 2a,15Reacts with NBS to give 2-pyridinylmethyl bromide1 Three To get. In step 2b, this intermediate15Treated with potassium permanganate To give the corresponding picolinic acid. In step 3b, first the acid16The N -Methoxy-N-methylamide, then reacted with LAH to give 5-bromo-2- Pyridinecarboxaldehyde (14) Is provided.                           Reaction formula VIII   Figure VIII shows the synthesis of 2-amino-5-picoline (Aldrich) Lomo-5-bromomethylpyridine (17) And 2-bromo-5-pyridinecarbox Aldehyde (18) Production. In step 1, 2-amino-5-picoli Reaction with bromine in the presence of hydrobromic acid and sodium nitrite at 0 ° C. Bromo-5-picoline (19) Is obtained. In step 2a,19Reacts with NBS Let me give you 3-pyridinylmethyl bromide17To get. In step 2b, the Intermediate19Is treated with potassium permanganate to give the corresponding nicotinic acid.20Get ． In step 3b, the acid20First to its N-methoxy-N-methylamide And then reduced with LAH to give 2-bromo-5-pyridinecarboxaldehyde (18 ) Is obtained.                             Reaction Diagram IX   The synthetic reaction scheme IX shows the aminoamide6Is it a TFA salt (prepared in Reaction Scheme III)? Et al. (4-Bromobenzyl) imidazol-2-one21Shows the production of. In process 1 In addition, TFA salt6In the presence of triethylamine and anhydrous magnesium sulfate. -React with imine by reacting with bromobenzaldehyde22To get. In step 2, Imine22Substituted benzylamine by reacting with sodium borohydride23Got The Benzylamine in step 323A suitable isocyanate7React with Substituted benzylurea24To get. In step 4, urea24First organic lichi Um reagent R⁷-Li [or R⁷= H, lithium aluminum hydride (L AH)] and then with dilute aqueous acid to give the desired 3- (4-bromobenzene). To obtain benzyl) imidazol-2-one.                             Reaction diagram X   Synthetic reaction diagram X shows aminoamide6Is it a TFA salt (prepared in Reaction Scheme III)? 3- (5-bromo-2-pyridinylmethyl) imidazol-2-one25Manufacturing Show. In step 1, TFA salt6With triethylamine and anhydrous magnesium sulfate 5-bromo-2-pyridinyl aldehyde in the presence of14(Manufactured in Reaction Diagram VII ) React with imine-26To get. In step 2, imine26Hydrogenated Substituted benzylamine by reacting with sodium arsenide27To get. In step 3 , Benzylamine27A suitable isocyanate7Substituted benzyl urine by reacting with Elementary28To get. In step 4, urea28First the organolithium reagent R⁷-Li [Or R⁷= Li Hanoreminium hydride (LAH)] And then react with dilute aqueous acid to give the desired 3- (5-bromo-2-pyridinyl methane Chill) imidazol-2-one25To get.                             Reaction Diagram XI   Synthesis Scheme XI shows aminoamide6TFA salt (prepared in Reaction Scheme III) From 3- (2-bromo-5-pyridinylmethyl) imidazol-2-one29Manufacturing of Shows. TFA salt in step 16With triethylamine and anhydrous magnesium sulfate 2-bromo-5-pyridinyl aldehyde in the presence of18(Made in Reaction Diagram VIII Imine by reacting with30To get. In step 2, imine30Hydrogenated Substituted benzylamine by reacting with sodium arsenide31To get. In step 3 , Benzylamine31A suitable isocyanate7Substituted benzylurea by reacting with32 To get. In step 4, urea32First the organolithium reagent R⁷-Li [ Or R⁷= H, lithium aluminum hydride (LAH)] , Followed by reaction with dilute aqueous acid to give the desired 3- (2-bromo-5-pyridinylmethyl ) Imidazol-2-one29To get.                             Reaction Diagram XII   Synthetic Reaction Diagram XII shows the parent imidazol-2-one5(Reaction Diagram IV, Reaction Diagram V Or (prepared in Reaction Scheme VI) from 3- (4-bromobenzyl) imidazole-2- on21, 3- (5-Bromo-2-pyridinylmethyl) imidazol-2-one25, And 3- (2-bromo-5-pyridinylmethyl) imidazol-2-one29Manufacturing of Shows. Imidazole-2-one5First with a base such as potassium t-butoxide And then the alkylating agent, 4-bromobenzyl bromide,13(Reaction Diagram VII Manufactured in), and17(Prepared in Reaction Diagram VIII), 3- (4- Bromobenzyl) imidazol-2-one21, 3- (5-Bromo-2-pyridinylme Chill) imidazol-2-one25, And 3- (2-bromo-5-pyridinyl) imi Dazol-2-one29Respectively get.                             Reaction Diagram XIII   Synthetic reaction diagram XIII shows boric acid1(Prepared in Reaction Diagram I and Reaction Diagram II) And bromoimidazol-2-one coupling reagent25(Reaction Diagram X and Reaction 3-[[5- [2- (1H-tetrazol-5-yl) furan from Figure XII) [Ethyl] -2-pyridinyl] methyl] -2H-imidazol-2-one30Showing the manufacture of I will. Boric acid1Sneak's Coupling [M.J.Sharp & V.Snieckus, Te [rahed ronLeL [., 5997 (1985)], in the presence of a palladium zero catalyst, bromine. Midazol-2-one coupling reagent25And angiotensin of the present invention Syn II antagonist30To get.                             Reaction Diagram XIV   Synthetic reaction diagram XIV shows boric acid1(Manufactured in Reaction Diagram I and Reaction Diagram II) And promoimidazol-2-one coupling reagent29(Reaction diagram XI and reaction diagram 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] from XII) Nyl] -3-pyridinyl] methyl] -2H-imidazol-2-one31Showing the manufacture of ． Boric acid1Sneak's Coupling [M.J.Sharp & V.Snieckus, Tetrahedro nLett., 5997 (1985)] in the presence of a palladium zero catalyst. Dazol-2-one coupling reagent29And angiotensin of the present invention II antagonist31To get.                             Reaction Diagram XV   Synthetic Reaction Diagram XV shows the corresponding 3- (4-bromobenzyl) imidazole-2-o. The21Imidazole-2-o from (prepared in Scheme IX and Scheme XII) 1 shows the production of a boronic acid coupling reagent. Equivalent by halogen-metal exchange Lithium species21Is generated and reacted with trimethylborate. Liberation Imidazol-2-one boric acid coupling reagent32Is produced by acid hydrolysis.                             Reaction Diagram XVI   Synthesis reaction diagram XVI shows 4-bromopyridine coupling test from nicotinic acid. medicine33[R²= CON (CH₃) C (CH₃)₃] And 2-bromopyridine cup Ring reagent34[R⁹= CON (CH₃) C (CH₃)₃] Is shown. In process 1 In addition, N-tert-butyl-N-methylnicotinamide was replaced with nicotinoyl chloride. And N-tert-butyl-N-methylamine. In step 2, s Mixture of regioisomeric anions by orthomethallylation with ec-butyllithium A compound was obtained, which was reacted with trimethylsilyl chloride and then with bromine in acetic acid. Is converted to the corresponding bromide by treatment with and the positional isomers are separated by chromatography. Then,33and34Is obtained.                             Reaction Diagram XVII   Synthetic reaction scheme XVII shows 3-bromopyridine coupling from isonicotinic acid. reagent35[R⁹= CON (CH₃) C (CH₃)₃] Is shown. In step 1 Uses N-tert-butyl-N-methylisonicotinamide as an isonicotinol chloride. Prepared from lid and N-tert-butyl-N-methylamine. In step 2 Reacts with sec-butyllithium to give ortholithiated species, which Corresponding by reacting with trimethylsilyl chloride and then treating with bromine in acetic acid Bromide35Is converted to.                             Reaction Diagram XVIII   Synthetic Reaction Diagram XVIII shows the coupling of 3-bromopyridine from picolinic acid. reagent36[R⁹= CON (CH₃) C (CH₃)₃] Is shown. In step 1 Is a solution of N-tert-butyl-N-methylpicolinic acid amide with picolinoyl chloride. And N-tert-butyl-N-methylamine. In step 2, s An ortholithiated species is obtained by reaction with ec-butyllithium, which is trimethyl Reaction with silyl chloride followed by treatment with bromine in acetic acid gives the corresponding bromide. Do36Is converted to.                             Reaction Diagram XIX   Synthetic Reaction Diagram XIX is common to imidazol-2-oneboronic acid32(Reaction Diagram XV ) And corresponding bromo coupling reagents36(Reaction Diagram XVIII),33( Reaction diagram XVI),35(Reaction Diagram XVII) and34(Reaction Scheme XVI) (Dinylbenzyl) imidazol-2-one37,38,39and40Showing the manufacture of I will. Boric acid32Sneak's Coupling [M.J.Sharp & V.Snieckus, Tetrah edronLet L., 5997 (1985)], in the presence of a palladium zero catalyst. Coupling reagent36,33,35and34Of the present invention. Angiotensin II antagonist37,38,39and40To get.                             Reaction diagram XX   Synthetic Reaction Diagram XX shows carboxylic acid analogs41And 1-H-tetrazole analoguesFour 2 Of R^Five= CON (CH₃) C (CH₃)₃Production from analogs with. Work In step 1, N-tert-butyl-N-methylamide analog43The trifluo Reaction with N-methylamide under reflux with acetic acid44To get. In step 2, N-methylamide44Reacts with sodium nitrite in acetic anhydride / acetic acid at 0 ° C The corresponding N-methyl-N-nitrosamide45To get. In step 3 , N-methyl-N-nitrosamide45Is hydrolyzed in a base, A carboxylic acid angiotensin II antagonist is obtained. In step 4 Is an acid analog41React with oxalic acid chloride and then with anhydrous ammonia, Primary amide46To get. In step 5, amide46To 50 ° C in carbon tetrachloride React with triphenylphosphine to give the corresponding nitrile47To get. Work In step 6, nitrile47Reacts with trimethyltin azide under reflux in xylene Then, the 1H-tetrazole angiotensin II antagonist of the present invention was obtained. Be done.                             Reaction Diagram XXI   Synthetic Reaction Diagram XXI shows suitable benzoic acid analogs49Organozinc reagent from48of Shows manufacturing. In step 1, analogs49In the presence of a suitable catalyst such as iron 2-Bromo analogue by bromination with bromineFiftyTo get. In step 2, 2-bromo AnalogFiftyAt -78 ° C in THF by a method known as halogen-metal exchange. Organolithium reagent by reacting with n-butyllithium51Converted to. As an alternative Organolithium reagent51Is49In THF at -78 ° C in the presence of a suitable complexing agent. Or in the absence of alkyl lithium reagents such as sec-butyl lithium / TM Reacting with EDA (N, N, N ', N-tetramethyl-ethylenediamine) Can also be generated directly by. In step 3, organolithium reagent5 1 Was treated with anhydrous zinc chloride at -78 ° C and then allowed to warm to room temperature. I raised it. Organozinc reagent48Was generated and used in situ.                             Reaction Diagram XXII   In the synthetic reaction diagram XXII,15(Reaction Diagram VII) and1-9From (Reaction Diagram VIII), 2-pyridinyl alkylating reagent52And 3-pyridinyl alkylating reagent53 Shows the production of. In step 1,15and19The sneaks condition (anti Using Fig. XIII)1, Or Negishi's condition [E.Negishi, A.O.King & N.Okuk ado,J.Org.Chem.,42, 1821 (1977)]48And then Each54and55Got. In step 2, the coupled biaryl compound Stuff54and55Were brominated with NBS / AIBN to give 2-pyridyl Nylalkyl reagent52And 3-pyridinylalkyl reagents53Got.                             Reaction Diagram XXIII   The synthetic reaction diagram XXIII shows the parent imidazol-2-one.5(Reaction Diagram IV, Reaction Diagram V , Or prepared in Reaction Scheme VI) from 3-[[5- [2- (1H-tetrazole- 5-yl) phenyl] -2-pyridinyl] methyl] -2H-imidazol-2-oneThree 0 (R^Five= CN_FourH) and 3-[[6- [2- (1H-tetrazol-5-yl) phene] Nyl] -3-pyridinyl] methyl] -2H-imidazol-2-one31(R^Five= CN_Four H) is shown. Imidazole-2-one5First with a base such as potassium t- Butoxide, then alkylating reagent52Or53(Reaction Diagram XXII) And 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-], respectively. Pyridinyl] methyl] -2H-imidazol-2-one30(R^Five= CN_FourH) and 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one31(R^Five= CN_FourH) was obtained.                             Reaction Diagram XXIV   Synthetic Reaction Diagram XXIV shows 4-methylphenylboronic acid from 4-bromotoluene. (56) Production. In step 1, 4-bromotoluene and metal magnesi Um was reacted in ether under reflux to form the Grignard reagent. Process 2 In, the THF solution of trimethoxyborane was cooled to −78 ° C. Treated with Niall reagent. In step 3, the boric acid ester is treated with an aqueous hydrochloric acid solution. 4-methylphenylboronic acid (56) Was obtained.                             Reaction Diagram XXV   The synthetic reaction diagram XXV shows 2-amino-3-picoline (58) (Aldrich) Rukylation reagent 2- (4-bromomethylphenyl) -3-cyanopyridine (57) 8 Shows process manufacturing. In step 1, aminopicoline58Bromine, concentrated hydrobromic acid And bromopicoline by reaction with sodium nitrite at 0 ° C59Converted to. Work In Step 2, picoline59KMnO_FourCorresponding carboxylic acid by60Acid It became. In step 3, acid60Alcohol with borane / THF61Reduced to It was. In step 4, alcohol61Under swane conditions or MnO₂For And aldehyde62Oxidized to. In step 5, aldehyde62The hydro Oxime reacted with xylamine63Got. In step 6, the oxime6 Three Was refluxed with acetic anhydride to give 2-bromo-3-cyanopyridine (64). Work In step 7, nitrile64Using sneaks conditions (Reaction Diagram XIII) Methylphenylboronic acid (56) (Reaction Diagram XXIV) Ano-2- (4-methylphenyl) pyridine (65) Was obtained. In step 8,65 Brominated with NBS / AIBN under reflux in carbon tetrachloride to give the desired alkylation test. medicine57Got.                             Reaction Diagram XXVI   In the synthetic reaction diagram XXVI, 4-picoline (67) (Aldrich) Drug 3- (4-bromomethylphenyl) -4-cyanopyridine (66) 6-step manufacturing Show. In step 1, 4-picoline was added to bromine by bromine in fuming sulfuric acid at high temperature. 3-bromo-4-picoline (68) Was obtained. In step 2, picoline6 8 KMnO_FourCorresponding carboxylic acid69Oxidized to. In step 3, acid6 9 Is first converted to its acid chloride with oxalic acid chloride and then treated with concentrated ammonia. Amide70Got. In step 4, amide70At high temperature₂O_FiveBy Treated with 3-bromo-4-cyanopyridine (71). In step 5 Is nitrile71Using sneaks conditions (Reaction Diagram XIII) Ruboric acid (56) (Reaction Scheme XXIV), 4-cyano-3- ( 4-methylphenyl) pyridine (72) Was obtained. In step 6,72The four salt Desired alkylating reagent by bromination with NBS / AIBN under reflux in carbon dioxide66Got It was.                             Reaction Diagram XXVII   In the synthetic reaction diagram XXVII, 4-bromopyridine (74) (Aldrich) Killing reagent 4- (4-bromomethylphenyl) -3-cyanopyridine (73) 5 works Indicates manufacturing. In Step 1, the reaction was conducted by LDA in THF at -78 ° C. Tobromocarbanion is generated and reacted with anhydrous DMF to give 4-bromo-3-carboxanone. Ruboxaldehyde75Got. In step 2, the aldehyde75The hydroxy Oxime reacted with silamine76Got. In step 3, the oxime76 Was dehydrated to 1,1'-carbonyldiimidazole under reflux in methylene chloride. 4-bromo-3-cyanopyridine (77) Was obtained. In step 4, nitrile7 7 4-methylphenylboronic acid (reaction diagram XIII)5 6 ) (Reaction Scheme XXIV), 3-cyano-4- (4-methylphenyl) Le) pyridine (78) Was obtained. In step 5,78Under reflux in carbon tetrachloride , Brominated with NBS / AIBN to give the desired alkylating reagent73Got.                             Reaction Diagram XXVIII   Synthetic Reaction Diagram XXVIII contains 3-bromopyridine (80) (Aldrich) Killing reagent 2-cyano-3- (4-bromomethylphenyl) pyridine (79) 4 works Indicates manufacturing. In step 1, pyridine80With hydrogen peroxide under reflux in acetic acid Pyridine N-oxide81Got. In step 2, N-oxide8 1 Of trimethylsilyl cyanide and triethylamine under reflux in acetonitrile. 3-bromo-2-cyanopyridine (82). In process 3 The nitrile82Using the conditions of Sneakz (Reaction Diagram XIII). Phenylboric acid (56) (Reaction Scheme XXIV) to couple with 2-cyano-3- (4-methylphenyl) pyridine (83) Was obtained. In step 4,83The four Bromination with NBS / AIBN under reflux in carbon chloride to give the desired alkylating reagent79To Obtained.                             Reaction Diagram XXIX   Synthetic Reaction Diagram XXIX shows the parent 1,4,5-trisubstituted-1,3-dihydro-2H-yl. Midazol-2-one5(Produced in Reaction Diagram IV, Reaction Diagram V, or Reaction Diagram VI) 1,4,5-trisubstituted-1,3-dihydro-3-[[4- (2-cyano-3-pyridy Nyl) phenyl] methyl] -2H-imidazol-2-one37(R^Five= CN), 1 , 4,5-Trisubstituted-1,3-dihydro-3-[[4- (3-cyano-4-pyridinyl) Phenyl] methyl] -2H-imidazol-2-one38(R^Five= CN), 1, 4, 5-trisubstituted-1,3-dihydro-3-[[4- (4-cyano-3-pyridinyl) phenyi] ] Methyl] -2H-imidazol-2-one39(R^Five= CN), and 1,4 5-trisubstituted-1,3-dihydro-3-[[4- (3-cyano-2-pyridinyl) phenyi ] Methyl] -2H-imidazol-2-one40(R^Five= CN). I Midazol-2-o5Is first treated with a base such as potassium t-butoxide, Then alkylating reagent79(Reaction Diagram XXVIII),73(Reaction Diagram XXVII),66 (Reaction Diagram XXVI) and57(Reaction Diagram XXV) Product37(R^Five= CN),38(R^Five= CN),39(R^Five= CN) and40 (R^Five= CN).                             Reaction diagram XXX   Synthetic reaction diagram XXX shows commercially available 1,3-dimethylcyclohexene (Wiley Organic 2H-imidazol-2-one from s)5(Q = 2α, 6β-dimethyl-1β- Cyclohexyl; R⁷= H; R⁸= Butyl) stereospecific synthesis. In process 1 Then, the olefin was added to 9-borabicyclo [3.3.1] nonane in diglyme ( 9-BBN) to react with 2α, 6β-dimethyl-1β-cyclohexylborane I got a thing. In step 2, the borane adduct is converted to hydroxylamine-O-sulfone. Reaction with acid gave the corresponding amine which retained its stereochemistry. In step 3 , Amine treated with 1,1'-carbonyldiimidazole (CDI) C) to generate acyl imidazole, which is then6(Reaction Diagram IV) Urea corresponding to reacting with8Got. In step 4, urea amide8LAH To give the corresponding urea aldehyde, which is treated with aqueous potassium bisulfate solution. 2H-imidazol-2-one5(Q = 2α, 6β-dimethyl-1β-cyclohexyl Le; R⁷= H; R⁸= Butyl). Cyclization of crude material in chloroform Stir at reflux for 3 hours in the presence of catalytic amount of trifluoroacetic acid (TFA) It was completed by this.                             Reaction Diagram XXXI   Synthetic reaction diagram XXXI shows commercially available 2-methylcyclohexanone (Ardrich) , Maternal 2H-imidazol-2-one5(Q = 2,2-dimethylcyclohexyl ; R⁷= H; R⁸= Butyl) as a diastereomeric mixture. Work In Step 1, hydroxyenone was added to formic acid ethyl ester and sodium methoxide. It was prepared by reaction with anions generated by xide. In step 2 Is the reaction of hydroxyenone with n-butyl mercaptan in the presence of acid. Was converted to the corresponding butylthioeneone by and. In process 3, in the 2nd place The regiospecific anion in is generated by potassium tert-butoxide, Reaction with methyl iodide gave the corresponding 2,2-dimethyl analog. In process 4 Then, the protective group was removed with an aqueous potassium hydroxide solution to remove 2,2-dimethylcyclohexa I got a non. In step 5, hydroxyamine salt in the presence of sodium acetate The oxime was obtained by reaction with the acid salt. In step 6, the oxime is returned with LAH Originally 2,2-dimethylcyclohexylamine was mixed with a mixture of diastereomers I got it. In step 7, the amine is treated with CDI and the acylimid is treated with in situ. This produces dazole, which is then aminoamide6(Reaction Diagram IV) Hit urea8Got. In step 8, urea amide8Is equivalent to LAH Reduced to aldehyde and returned in chloroform in the presence of catalytic amount of TFA for 3 hours. The mixture was stirred down and cyclized.   The following examples describe details of methods for preparing compounds of formula I. These detailed It is intended that the description be included within the scope of the invention and that it forms part of the invention described above. This is an example of a general synthesis operation. These detailed descriptions are provided for illustrative purposes. However, it is not intended to limit the scope of the present invention. Especially instructions Unless otherwise noted, all parts are parts by weight and temperatures are given in degrees Celsius.                             Example 1 1-Cyclopentyl-4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetra Zol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2- on   Step 1:1-cyclopentyl-4-butyl-1,3-dihydro-2H-imidazole- 2-on manufacturing   1-Cyclopentyl-4-butyl-1,3-dihydro according to Synthetic Reaction Schemes III and IV -2H-imidazol-2-one was prepared. NMR (CDCl₃) Δ 0.91 (t ,J= 8 Hz, 3H), 1.29-1.42 (m, 2H), 1.48-1.85 ( m, 10H), 1.98-2.12 (m, 2H), 2.47 (td,J= 8 and 1Hz, 2H), 4.44-4.57 (m, 1H), 5.88 (t,J= 1H z, 1H), 10.22 (brs, 1H); MS (FAB) m / e (relative intensity) 209 (100), 141 (43); HRMS. Calculated value as M + H: 209 ． 1654, analytical value: 209.1656.   Process 2:1-cyclopentyl-4-butyl-1,3-dihydro-3-[[6- [2- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Manufacture of Dazol-2-one   Imidazole from Step 1 according to synthetic scheme XII and XIV or XXIII- 2-one is converted to 1-cyclopentyl-4-butyl-1,3-dihydro-3-[[6- [2- (1 H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole Converted to zol-2-one. Colorless solid. NMR (CDCl₃) Δ 0.88 (t ,J= 7 Hz, 3H), 1.30-1.40 (m, 2H), 1.41-1.52 ( m, 2H), 1.56-1.86 (m, 6H), 2.02-2.14 (m, 2H) , 2.27 (t,J= 7 Hz, 2H), 4.55 (m,J= 7Hz, 1H), 4 ． 97 (s, 2H), 5.98 (s, 1H), 7.27 (d,J= 8Hz, 1H ), 7.44-7.54 (m, 3H), 7.62 (dd,J= 8 and 2 Hz, 1H), 7.98-8.05 (m, 1H), 8.48 (d,J= 2Hz, 1H) MS (FAB) m / e (relative intensity) 444 (100), 416 (12), 40 1 (6), 387 (4), 233 (13), 209 (22), 194 (12), 180 (25); HRMS. Calculated as M + H: 444.2512, analytical value : 444.2518.                             Example 2 1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetra Zol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2- on   Step 1:1-cyclohexyl-4-butyl-1,3-dihydro-2H-imidazole- 2-on manufacturing   According to the synthetic reaction scheme III and IV, 1-cyclohexyl-4-butyl-1,3-dihydride Ro-2H-imidazol-2-one was prepared. NMR (CDCl₃) Δ 0.91 ( t,J= 7 Hz, 3H), 1.05-1.24 (m, 2H), 1.26-1.46 (M, 4H), 1.47-1.58 (m, 2H), 1.63-1.76 (m, 2H) ), 1.78-1.96 (m, 4H), 2.36 (td,J= 8 and 1 Hz, 2H), 3.87-4.00 (m, 1H), 5.89 (t,J= 1Hz, 1H) , 9.82 (br s, 1H); MS (FAB) m / e (relative intensity) 223 (1 00), 141 (53); HRMS. Calculated as M + H: 223.1810 , Analytical value: 223.1738.   Process 2:1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Manufacture of Dazol-2-one   Imidazole from Step 1 according to synthetic scheme XII and XIV or XXIII- 2-one is converted into 1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- (1 H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole Converted to zol-2-one. Colorless solid; melting point 202-203 ° C. (decomposition);   NMR (CDCl₃) Δ 0.89 (t,J= 8Hz, 3H), 1.08-1.2 4 (m, 2H), 1.26-1.54 (m, 7H), 1.6-1.76 (m, 1 H), 1.77-2.00 (m, 4H), 2.28 (t,J= 8Hz, 2H), 3.95-4.07 (m, 1H), 4.97 (s, 2H), 6.00 (s, 1H) ), 7.32 (d,J= 8 Hz, 1H), 7.45-7.55 (m, 3H), 7 ． 69 (dd,J= 8 and 2 Hz, 1H), 7.96-8.04 (m, 1H) , 8.47 (d,J= 2 Hz, 1 H); MS (FAB) m / e (relative intensity) 45 8 (56), 430 (19), 237 (19), 208 (100), 194 (3 6), 180 (76); HRMS. Calculated as M + H: 458.2668, min Analysis value: 458.2732.                             Example 3 1- (2α, 6α-1β-cyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one   Step 1:1- (2α, 6α-Dimethyl-1-cyclohexyl) -4-butyl-1,3- Preparation of dihydro-2H-imidazol-2-one   According to the synthetic reaction diagram XXX, 1- (2α, 6α-dimethyl-1β-cyclohexyl ) -4-Butyl-1,3-dihydro-2H-imidazol-2-one was prepared. NMR (CDCl₃) Δ 0.78 (d,J= 7 Hz, 6 H), 0.90 (t,J = 7 Hz, 3H), 1.08-1.26 (m, 2H), 1.26-1.40 (m, 3H), 1.46-1.59 (m, 4H), 1.6-1.85 (m, 3H), 2 ． 37 (t,J= 7 Hz, 2H), 3.35 (t,J= 11 Hz, 1H), 5. 48 (s, 1H), 9, 80 (br s, 1H); MS (FAB) m / e (relative Intensity) 251 (100), 141 (58).   Process 2:1- (2α, 6α-dimethyl-1β-cyclohexyl) -4-butyl-1, 3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pi Preparation of ridinyl] methyl] -2H-imidazol-2-one   Imidazol-2-one from Step 1 according to synthetic scheme XXII and XXIII 1- (2α, 6α-dimethyl-1β-cyclohexyl) -4-butyl-1,3-dihydr B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Mechi [2H] -imidazole-2-one. Colorless solid. NMR (CDCl₃ ) Δ 0.77 (d,J= 7 Hz, 6 H), 0.88 (t,J= 7 Hz, 3 H), 1. 06-1.39 (m, 5H), 1.41-1.63 (m, 4H), 1.65-1. 86 (m, 3H), 2.27 (t,J= 7 Hz, 2H), 3.41 (br t,J = 11 Hz, 1H), 5.00 (s, 2H), 5.90 (s, 1H); 7.1 6 (d,J= 8 Hz, 1H), 7.42-7.48 (m, 3H), 7.52 (d d,J= 8 and 2 Hz, 1H), 7.86-7.91 (m, 1H), 8.38 (D,J= 2 Hz, 1 H); MS (FAB) m / e (relative intensity) 486 (100 ), 458 (21), 443 (6), 429 (6), 237 (15), 209 ( 47), 194 (20), 180 (51); HRMS. Calculated value as M + H: 486.2918, analytical value: 486.2918.                             Example 4 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one   Step 1:1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro -2H-Imidazol-2-one production   According to the synthetic reaction diagram XXXI, 1- (2,2-dimethylcyclohexyl) -4-butyl Lu-1,3-dihydro-2H-imidazol-2-one was prepared. NMR (CDCl₃ ) Δ 0.91 (t,J= 7 Hz, 3H), 093 (s, 6H), 1.21-1. 87 (m, 12H), 2.35 (t,J= 8 Hz, 2H), 3.59 (dd,J = 13 and 4 Hz, 1H), 5.80-5.85 (m, 1H), 10.2 (s , 1H).   Process 2:1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one   Imidazol-2-one from Step 1 according to synthetic scheme XXII and XXIII 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[ 6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- Converted to 2H-imidazol-2-one. Colorless solid. NMR (CDCl₃) Δ0 ． 79 (s, 3H), 0.82 (t,J= 7 Hz, 3H), 0.89 (s, 3H ), 1.20-1.50 (m, 10H), 1.69-1.95 (m, 2H), 2. 23 (t,J= 7 Hz, 2H), 3.77 (dd,J= 14 and 3 Hz, 1H), 7.78 (d ,J= 15 Hz, 1 H), 7.83 (d,J= 15 Hz, 1 H), 6.23 (s , 1H), 7.40 (d,J= 8 Hz, 1H), 7.53 (dd,J= 8 and 2Hz, 1H), 7.58-7.78 (m, 4H), 8.20 (d,J= 2 Hz , 1H); MS (FAB) m / e (relative intensity) 486 (47), 458 (32) , 243 (26), 209 (100), 180 (78), 141 (40); HR MS. Calculated as M + H: 486.2981, analytical value: 486.2979.                             Biological evaluation   Assay A: Angiotensin II binding activity   The compounds of the present invention were tested for smooth muscle angiolysis using rat endometrial preparation. It was tested for its ability to bind to the tensin II receptor. Angiotensin (AII) is I purchased it from Peninsula Labs.¹²⁵I-angiotensin II (specific activity 2200Ci / Mmol) was purchased from Du Pont-New England Nuclear. Assay is Douglas Method [Endocrinology,106, 120-124 (1980)]. Rat pup Miyanomiya was prepared from fresh tissue. All operations were performed at 4 ° C. Uterus To remove fat from the solution, and then in phosphate buffered saline containing 5 mM EDTA, pH 7.4. Homogenized. Centrifuge the homogenate at 1500 xg for 20 minutes and collect the supernatant. It was then re-centrifuged at 100,000 xg for 60 minutes. Pellet 2 mM EDT Final protein in buffer (pH 7.5) consisting of A and 50 mM Tris hydrochloride It was resuspended to a concentration of 4 mg / ml. Assay test tube with 5 mM MgC 1₂, 2 mM EDTA, 0.5% bovine serum albumin, 50 mM Tris hydrochloride, pH 7.5 and¹²⁵I-AII (about 10^Fivecpm) in the absence of unlabeled ligand Or filled in the presence. The reaction is initiated by the addition of membrane proteins and the mixture is Incubated for 60 minutes at 25 ° C. Incubation was ice-cold 50 mM It was terminated by Tris hydrochloride (pH 7.5) and the mixture was filtered and bound to the membrane. The labeled peptide was separated from the free ligand. Incubation test tubes and The filters and filters were washed with ice-cold buffer. About filters, Micromedic Radioactivity was measured with a gamma counter. Non-specific binding is 10 μM unlabeled AII Was defined as a bond in the presence of. Specific binding changes from total binding to nonspecific binding Calculated by subtracting. The receptor binding affinity of AII antagonist compounds is high Specific binding from the sex AII receptor¹²⁵Test AII Ant giving 50% substitution of I-AII Concentration of gonist (IC₅₀). The combined data is a nonlinear least squares curve It was analyzed by a fitting program. The results are listed in Table I.   Assay B: In vitro vascular smooth muscle response to AII   The compounds of the present invention were tested for antagonist activity in the rabbit aortic ring. did. Phenobarbiter Male New Zealand White Rabbit (2-2.5kg) Le Was sacrificed by an overdose of and was exsanguinated from the carotid artery. The thoracic aorta was removed and attached The fat and connective weave were removed and then cut into 3-mm ring segments. Gently slide a rolled piece of filter paper through the lumen of the vessel to remove endothelium from the annulus. ． This was then placed in a tissue bath with water overcoat and connected to a 7D Grass Polygraph F T03 Grass Transducer with movable end combined with stainless steel wire movable end. And held at 37 ° C between the fixed ends and the isometric force response was recorded. In the tissue bath The following composition (mM): 130 NaCl, 15 NaHCO₃, 15 KCI, 1. 2NaH₂PO4, 1.2 MgSO_Four, 2.5 CaCl₂, And 11.4 guru Full of oxygenated (95% oxygen / 5% carbon dioxide) Krebs solution consisting of a course I played. After equilibrating the preparation for 1 hour, about 1 g Passive tension was applied. The angiotensin II concentration-response curve was then recorded (3 x 10^-Ten~ 1 × 10^-FiveM). Each concentration of AII induces its maximal contraction, then repeated. After returning AII was washed out for 30 minutes, a higher concentration of AII was re-challenged. 10 aortic rings^-FiveAfter exposure to the test antagonist with M for 5 minutes, AII is I struck. Adjacent segments of the same aortic ring were Was used for all concentration-response curves in the absence. With test compound Efficacy is pA₂Expressed by value, H.0.Schild [Br.J.Pharmacol.Chemother.,2, 189-2 06 (1947)]. pA₂Value is EC for AII₅₀Value is factor 2 This is the concentration of the antagonist that increases only by. Two rabbits for each test agonist We evaluated the aortic rings from. The results are shown in Table I.   Assay C: In Vivo Intragastric Pressure Assay Response to AII Antagonists   Male Sprague-Dawley rats (225-300 g) were loaded with methohexital (3 Anesthesia (0 mg / kg, intraperitoneal injection) and insert catheter into femoral artery and vein did. The catheter was exposed subcutaneously in the posterior part of the head and between the shoulder blades. The catheter was filled with heparin (1000 units / ml saline). Rat The rats were returned to the cage and fed normal rat chow and water ad libitum. I completely recovered from the surgery Then (3 to 4 days), place the rat in the holder of lucite and press the arterial line Connected to a juicer. Arterial pressure was recorded by Gould Polygraph (mmHg) ． Angiotensin II was administered through a venous catheter with 0.2 ml saline perfusion. To It was administered as a 30 ng / kg bolus delivered in a 50 μl volume. Before injection The pressure response was measured in mmHg by the difference between the pulse pressure and the maximum pressure achieved. Injection of AII Every 10 minutes until three consecutive injections give a response within 4 mmHg of each other. Repeated. These three responses were then averaged to serve as the AII control response. Trial The test compound was suspended in 0.5% methylcellulose aqueous solution and administered intragastrically. Standard dose Was 3 mg / kg. A bolus injection of angiotensin II was given 30 times after intragastric administration. , 45, 60, 75, 120, 150 and 180 minutes. Then the rat , Returned to cage for further testing. There was a minimum of 3 days between trials. The% inhibition was calculated by the following formula at each time point after intragastric administration.             [(Control response-response at each time point) / control response] × 100 The results are shown in Table I.   The compounds of the present invention also include one or more compounds of Formula I, one or two. One or more non-toxic pharmaceutically acceptable carriers and / or adjuvants (hereinafter generic A "carrier" substance), and optionally other active ingredients The pharmaceutical composition of The compounds of the invention are preferably administered by any suitable route. Is a form of pharmaceutical composition adapted to such a route and is effective for the intended treatment. It can be given in doses. The invention required to prevent or halt the progression of a medical condition The therapeutically effective dose of a compound of the invention can be ascertained readily by a person of ordinary skill in the art of this invention. The These compounds and compositions can be administered intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically. It can be administered   For oral administration, the pharmaceutical composition may be, for example, a tablet, capsule, suspension or It can be in liquid form. Administration in which the pharmaceutical composition contains a specified amount of the active ingredient It is preferable to use the unit form. Examples of such dosage units are tablets or caps It is a cell agent. These are advantageously about 1-250 mg of active ingredient, preferably about 25 mg. Containing ~ 150 mg. In the case of mammals, an appropriate daily dose will depend on the patient's condition and And varies widely depending on other factors. However, the dose is per kg body weight 0.1 to 3000 mg / kg, especially about 1 to 100 mg per kg body weight is suitable Is.   The active ingredient also uses, for example, saline, dextrose or water as a carrier. The composition can also be administered by injection. An appropriate daily dose is 1 body weight About 0.1-100 mg / kg, 1 depending on the disease being treated It is injected several times a day. A preferred daily dose is about 1-3 per kg body weight. It is considered to be 0 mg / kg. Compounds applied in prophylactic therapy are preferably administered daily The daily dose generally ranges from about 0.1 mg / kg to about 100 mg / kg body weight. Given. A further preferred dosage is about 1 mg to about 100 mg / kg body weight. It will be a range. The most preferred dosage is from about 1 mg / kg to about 50 / kg body weight per day. The range is mg. The appropriate dose can be given as several divided doses daily. This These divided doses can be administered in a unit dosage form. Usually, the dose or divided dose is a unit It can contain from about 1 mg to about 100 mg of active compound per form. More preferable throw The dosage should contain from about 2 mg to about 50 mg of active compound per unit dosage form. U. Most preferred dosage forms contain from about 3 mg to about 25 mg of active ingredient per unit dose. ．   Dosage Criteria for Treatment of Disease Conditions with Compounds and / or Compositions of the Invention Is the type of patient, age, weight, sex and medical condition, severity of disease, route of administration , And according to various factors, including the particular compound used. Fluctuate over a wide range.   For therapeutic purposes, the compounds of the present invention will usually be the only one suitable for the indicated route of administration. Alternatively, it is blended with two or more kinds of auxiliary agents. When given orally, the compound is lactose Sucrose, sucrose, starch powder, cellulose ester of alkanoic acid, talc, starch Of formic acid, magnesium stearate, magnesium oxide, phosphoric acid and sulfuric acid Sodium and calcium salts, gelatin, gum acacia, sodium alginate Mixed with polyvinyl pyrrolidone, and / or polyvinyl alcohol, For convenience of administration, tablets or capsules should be filled. Such capsules also For tablets, for example, the active compound in hydroxypropylmethylcellulose. Dispersed controlled release formulations are included. Formulations for parenteral administration may be aqueous or non-aqueous It can be in the form of an isotonic sterile injection solution or suspension of. These solutions And suspensions of one or more of the above mentioned for use in formulations for oral administration. It can be prepared from sterile powders or granules containing the above carriers or diluents. Compound is water , Polyethylene glycol, propylene glycol, ethanol, corn Oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, salt, and / or each Dissolve in seed buffer. Other adjuvants and modes of administration are well known and well known in the pharmaceutical arts. It has been.   Although the present invention has been described in terms of particular embodiments, details of these embodiments Is not intended to be limiting.

[Procedure Amendment] Patent Act Article 184-8 [Submission date] October 10, 1994 [Correction content]   Family of compounds with one or two oxo substituents on the triazole ring Are known. For example, a special feature of East Germany announced on August 3, 1983 No. 160,447, 1,2,4-triazoline-5 used as a herbicide -One compounds family, especially 2,4-dihydro-4,5-bis (phenylmethyi) ) -3H-1,2,4-triazol-3-one. 1972 1 Berggie Patent No. 806,146 published on 16th October has a tranquilizer , Compounds with antihypertensive and analgesic activity, 3- (4-m-chlorophenyl-1-pipera Including dinyl) -propyl) -3,4-diethyl-1,2,4-triazolin-5-one A family of triazolinone compounds has been described. February 28, 1963 Belgian Patent No. 631,842, published in A family of 1,2,4-triazolones with anesthetic, sedative and analgesic activity is described Included in this is the 4-N-aralkyl-1,2,4-triazol-5-one compound Contains the class of. European Patent No. 7,1 published on June 15, 1978 No. 80 is 1,2-disubstituted-4-alkyl-1,2,4-triazolidine-3,5-di The ON family has been described and these have a wide variety of activities such as anti-ulcers, bronchi Dilation, antifertilization and cardiovascular related activities such as antihypertensive, antiarrhythmic, inhibition of platelet aggregation and And has smooth muscle activity. Europe published on March 18, 1987 Patent 283,310 describes the treatment of cerebrovascular and ischemic diseases and anoxia. N for protection against¹-Diarylmethyl-N²-Aminoalkyl-diaza-hete B-ring derivatives have been described.   EP-A 0 508 393 (only with PT specified), April 1, 1992 And filed April 6, 1992 claiming priority on April 5, 1991 , Published October 14, 1992, N-Alley for the treatment of cardiovascular disorders Ruheteroarylalkylimidazol-2-one compounds are disclosed.   WO-A 92/17469 also claims priority of April 5, 1991, The application was filed on April 1, 1992 and was published on October 15, 1992. N-arylheteroarylalkylimidazole-2-for the treatment of ring system disorders On compounds are disclosed.   WO-A 92/07834 shows angiotensin-II-antagonist activity N-substituted biphenylalkyl compounds having are disclosed.   EP-A 0 480 204 includes angiotensin-II-receptor antagonis. Described as tetraazolyl-phenyl / pyridyl-substituted imidazoles useful as It has been.   EP-A 0 475 898 is an N with hypotensive activity.¹-Biphenyl-Diaza-2 -On-heterocycle derivatives.   EP-A 0 412 594 describes angiotensin-II-antagonists as , Substituted triazolinones, triazolinthiones and triazolinimines disclosed Has been done.                             Description of the invention   N-substituted arylheteroants useful for the treatment of cardiovascular disorders, especially cardiovascular disorders The class of alkylalkyl 1-cycloalkyl-imidazol-2-one compounds is of formula I {In the formula, Q is [Where R¹, R², R³, R^Four, R^FiveAnd R⁶Independently hydrido and archi Ru, alkoxy, cyano, halo, hydroxy, nitro, amino, alkylamino , Carboxyl, alkoxycarbonyl, formyl, alkylcarbonyl and Selected from haloalkylcarbonyl; R¹And R²Further forms oxo with both May be done; R³And R^FourMay further form an oxo with both: R^FiveAnd And R⁶May further form oxo with each other; d, b and r are each 0 or To 5 (including 1 and 5), and the sum of d + b + r is 0. Is a number from 1 to 5 (including 1 and 5), but R on Q¹~ R⁶At least 2 Are selected from groups other than hydride or form groups other than hydride] A cycloalkyl group selected from R;⁷Is hydrido, alkyl, halo, ha Selected from lower alkyl, formyl, carboxyl and alkoxyalkyl; R⁸A Alkyl, phenyl, phenylalkyl, cycloalkyl and cycloalkyl Selected from ruquil; m is a number selected from 1 to 4 (including 1 and 4) R; A (In the formula, R⁹Is COOH and Is an acidic group selected from) acidic group-substituted pyridinyl-phenyl groups selected from Or a stereoisomer or tautomer thereof, Alternatively, it is a pharmaceutically acceptable salt thereof.   Regioisomers of compounds of formula I, especially substitutions at carbon atoms of the imidazole ring Formed by various substitutions at the nitrogen atom of the imidazole ring in the context of These positional isomers are also included as part of the present invention. For naming, in Formula I For the preferred set of compounds of the present invention included, the imidazole ring number The ring system is shown below. In the formula, Q, R⁷, R⁸, M and A are as defined above.   The compounds of formula I can be used for example in hypertension, congestive heart failure and arteriosclerosis Of various cardiovascular and cardiovascular-related disorders and glaucoma, including various cardiovascular disorders It is thought to be useful for the treatment of other disorders such as These compounds are also adjunct therapeutic agents However, it seems to be useful. For example, compounds of formula I may be It can also be used in combination with diuretics to treat blood pressure. Similarly, Compounds can also be used in conjunction with certain surgical procedures. For example, Compounds can be used to prevent restenosis after angioplasty.   The compound of formula I is an antagonist of the angiotensin II (AII) receptor, or By acting as a blocker, it is therapeutically effective in treating cardiovascular disorders. Are The Compounds Of Formula I Therapeutically Effective In The Treatment Of The Cardiovascular and Cardiovascular Disorders Described above? , Or may be a precursor or prodrug of a therapeutically effective compound It is done.   In Formula I, there are several groups of compounds that are of greater interest, as described below. For these compounds, "R on Q¹~ R⁶At least two other than hydrido Selected from groups or to form groups other than hydride "apply. The first group of more interest is the formula II Sopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pe Nil, isopentyl and neopentyl) or a compound thereof It is a stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof.   A family of particular compounds of particular interest in formula III (a) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocyclopropyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,3-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,3-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5 - 1- (2-oxo-3-isopropylcyclopropyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the first group of compounds of formula III there is a second class of compounds of even greater interest. And these compounds have the formula III (b) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula III (b) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocyclopropyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the first group of compounds of formula III there is a third class of compounds of even greater interest. And these compounds have the formula III (c) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula III (c) is the combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,3-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro - (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹-And R²Is even better with both May be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propy Ru, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl , N-pentyl, isopentyl and neopentyl)) Or its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof. The   A family of particular compounds of particular interest in formula III (d) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,3-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-3-methylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Chi Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula III (e) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,3-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3- [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-3-methylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one;   A family of particular compounds of particular interest in formula III (f) is the combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocyclopropyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,3-dimethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-3-methylcyclopropyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-3-methylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,3-diethylcyclopropyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-3-ethylcyclopropyl) -4-butyl-1,3-dihydro - May be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl, Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- Selected from pentyl, isopentyl and neopentyl) or Is a stereoisomer or tautomer of or a pharmaceutically acceptable salt thereof.   A family of particular compounds of particular interest in formula IV (a) is the compounds of the following groups: And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [2- ( 1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2,4-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-acetyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-oxocyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H imida Zo 1- (2,2-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the second group of compounds of formula IV there is a third class of compounds of even greater interest. , These compounds have the formula IV (c) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo May be formed: R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula IV (c), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- ( 1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2,4-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula IV (d), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2,4-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ] Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from Lifluoromethylcarbonyl: R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula IV (e) is the compounds of the following groups: And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- ( 1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2,4-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-acetyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl]- 2H-imidazol-2-one;   In formula IV (f), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Dazol-2-one; 1- (2,4-dimethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-isopropyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-acetyl-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxo-4-methylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-methyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[ 4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2,4-diethylcyclobutyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-4-ethylcyclobutyl) -4-butyl-1,3-dihydro- Three May be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl, Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- Selected from pentyl, isopentyl and neopentyl) or Is a stereoisomer or tautomer of or a pharmaceutically acceptable salt thereof.   In formula V (a), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-methylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Mi 1- (2,2-diethylcyclopentyl) -4-butyl-1, -3-dihydro-3-[[ 6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- It is a group of 2H-imidazol-2-ones.   Within the third group of compounds of Formula V there is a third class of compounds of even greater interest. , These compounds have the formula V (c) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride: R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula V (c), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula V (d), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3- [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-methylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Chi Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula V (e), a family of particular compounds of particular interest are compounds of the following groups: And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-methylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one;   In formula V (f), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-methylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,5-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro - Sopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pe Nil, isopentyl and neopentyl) or a compound thereof It is a stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof.   In formula VI (a), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,6-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-methylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,6-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5 - 1- (2-oxo-6-isopropylcyclohexyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl]- 2H-imidazol-2-one; and 1- (2,2-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fourth group of compounds of formula VI there is a second class of more interesting compounds , These compounds have the formula VI (b) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula VI (b), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fourth group of compounds of formula VI there is a third class of more interesting compounds , These compounds have the formula VI (c) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula VI (c), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,6-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro - (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula VI (d), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-ethyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-methylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Chi Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   In formula VI (e), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,6-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-methylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one;   In formula VI (f), a family of particular compounds of particular interest are compounds of the following groups And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is, 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,6-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro -3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-methylcyclohexyl) -4-butyl-1,3-dihydro- 3-[[4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-6-methylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [4- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,6-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-6-ethylcyclohexyl) -4-butyl-1,3-dihydro - Sopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pe Nil, isopentyl and neopentyl) or a compound thereof It is a stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof.   A family of particular compounds of particular interest in formula VII (a) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2,7-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-methylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-7-ethylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,7-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5 - 1- (2-oxo-7-isopropylcycloheptyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fifth group of compounds of Formula VII there is a second class of compounds of even greater interest. And these compounds have the formula VII (b) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VII (b) is the combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocycloheptyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the fifth group of compounds of Formula VII there is a third class of compounds of even greater interest. And these compounds have the formula VII (c) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VII (c) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,7-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1-(-2-ethyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-isopropyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro - (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro. Iodine. Bromo. Carboxyl. Formyl, methylcarbonyl and g Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VII (d) is a combination of the following groups: And its stereoisomeric and tautomeric forms, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,7-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-methylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Chi Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VII (e) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocycloheptyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,7-dimethylcycloheptyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2-H-imidazol-2-one; 1- (2-isopropyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-7-methylcycloheptyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-7-methylcycloheptyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; And its stereoisomers and tautomers, and its pharmaceutically acceptable salts Consists of. That is,   A family of particular compounds of particular interest in formula VIII (a) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocyclooctyl) -4-butyl-1,3-dihydro-3-[[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,8-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro -3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-methylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [[5- [2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [5- [2- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,8-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro - 1- (2,2-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[5 -[2- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the sixth group of compounds of formula VIII there is a second class of more interesting compounds. And these compounds have the formula VIII (b) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VIII (b) is the combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocyclooctyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,8-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; These compounds have the formula VIII (c) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VIII (c) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,8-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -2-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -2-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-methylcyclooctyl) -4-butyl-1,3-dihydro- Three (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VIII (d) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2,8-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-methylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [4- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [4- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] It is a stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof.   A family of particular compounds of particular interest in formula VIII (e) is the combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,8-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-ethyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-isopropyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro -3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-8-methylcyclooctyl) -4-butyl-1,3-dihydro- 3-[[4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [[4- [3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyi ]]-2H-imidazol-2-one; 1- (2-oxo-8-methylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-8-ethylcyclooctyl) -4-butyl-1,3-dihydro-3- [ [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,8-diethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; Cyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[3- (1H-Tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclooctyl) -4-butyl-1,3-dihydro-3- [4- [3- (1H-tetrazol-5-yl) phenyl] -4-pyridinyl] methyl] -2 It is a group of H-imidazol-2-ones.   Within the sixth group of compounds of formula VIII there is a sixth class of more interesting compounds. And these compounds have the formula VIII (f) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo R may be formed; R⁷Is a hydride: R⁸Is methyl, ethyl, n-propyl , Isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) compounds or Is its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof ．   A family of particular compounds of particular interest in formula VIII (f) is a combination of the following groups: And its stereoisomers and tautomers, and pharmaceutically acceptable salts thereof Consists of. That is, 1- (2-oxocyclooctyl) -4-butyl-1,3-dihydro-3-[[4- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,8-dimethylcyclooctyl) -4-butyl-1,3-dihydro-3-[[4 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H   The following examples describe details of methods for preparing compounds of formula I. These detailed It is intended that the description be included within the scope of the invention and that it forms part of the invention described above. This is an example of a general synthesis operation. These detailed descriptions are provided for illustrative purposes. However, it is not intended to limit the scope of the present invention. Especially instructions Unless otherwise noted, all parts are parts by weight and temperatures are given in degrees Celsius.                             Example 1 (comparative example) 1-Cyclopentyl-4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetra Zol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2- on   Step 1:1-cyclopentyl-4-butyl-1,3-dihydro-2H-imidazole- 2-on manufacturing   1-Cyclopentyl-4-butyl-1,3-dihydro according to Synthetic Reaction Schemes III and IV -2H-imidazol-2-one was prepared. NMR (CDCl₃) Δ 0.91 (t ,J= 8 Hz, 3H), 1.29-1.42 (m, 2H), 1.48-1.85 ( m, 10H), 1.98-2.12 (m, 2H), 2.47 (td,J= 8 and 1Hz, 2H), 4.44-4.57 (m, 1H), 5.88 (t,J= 1H z, 1H), 10.22 (br s, 1H); MS (FAB) m / e (relative intensity ) 209 (100), 141 (43); HRMS. Calculated value as M + H: 20 9.1654, analytical value: 209.1656.                             Example 2 (comparative example) 1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetra Zol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2- on   Step 1:1-cyclohexyl-4-butyl-1,3-dihydro-2H-imidazole- 2-on manufacturing   According to the synthetic reaction scheme III and IV, 1-cyclohexyl-4-butyl-1,3-dihydride Ro-2H-imidazol-2-one was prepared. NMR (CDCl₃) Δ 0.91 ( t,J= 7 Hz, 3H), 1.05-1.24 (m, 2H), 1.26-1.46 (M, 4H), 1.47-1.58 (m, 2H), 1.63-1.76 (m, 2H) ), 1.78-1.96 (m, 4H), 2.36 (td,J= 8 and 1 Hz, 2H), 3.87-4.00 (m, 1H), 5.89 (t,J= 1Hz, 1H) , 9.82 (br s, 1H); MS (FAB) m / e (relative intensity) 223 (1 00), 141 (53); HRMS. M + H, calculated value: 223.1810, analytical value: 223.173 8.   Process 2:1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imi Manufacture of Dazol-2-one   Imidazole from Step 1 according to synthetic scheme XII and XIV or XXIII- 2-one is converted into 1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- (1 H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole Converted to zol-2-one. Colorless solid; melting point 202-203 ° C. (decomposition);                                   Example 3 1- (2α, 6α-dimethyl-1β-cyclohexyl-4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one   Step 1:1- (2α, 6α-dimethyl-1β-cyclohexyl) -4-butyl-1, Preparation of 3-dihydro-2H-imidazol-2-one   1- (2α, 6α-dimethyl-1β-cyclohexyl) according to the synthetic reaction diagram XXX -4-Butyl-1,3-dihydro-2H-imidazol-2-one was prepared. NMR (CDCl₃) Δ 0.78 (d,J= 7 Hz, 6 H), 0.90 (t,J = 7 Hz, 3H), 1.08-1.26 (m, 2H), 1.26-1.40 (m, 3H), 1.46-1.59 (m, 4H), 1.6-1.85 (m, 3H), 2 ． 37 (t,J= 7 Hz, 2H), 3.35 (t,J= 11 Hz, 1H), 5. 48 (s, 1H), 9, 80 (br s, 1H); MS (FAB) m / e (relative Intensity) 251 (100), 141 (58).   Process 2:1- (2α, 6α-dimethyl-1β-cyclohexyl) -4-butyl-1, 3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pi Preparation of ridinyl] methyl] -2H-imidazol-2-one   Imidazol-2-one from Step 1 according to synthetic scheme XXII and XXIII 1- (2α, 6α-dimethyl-1β-cyclohexyl) -4-butyl-1,3-dihydr B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Mechi (In the formula, R⁹Is COOH and Is an acidic group selected from) acidic group-substituted pyridinyl-phenyl groups selected from Or its stereoisomers or tautomers or pharmaceuticals thereof Acceptable salt.   2. Formula II [Where R¹~ R⁶Are independently hydrido, methyl, ethyl, n-propyl, Isopropyl, tert-butyl, methoxy, ethoxy, propoxy, isoprop Poxy, tert-butoxy, cyano, fluoro, chloro, iodo, bromo, hu Droxy, nitro, amino, N-methylamino, N, N-dimethylamino, N-E Cylamino, N, N-diethylamino, carboxyl, methoxycarbonyl, d Toxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and tri Fluorome                               The scope of the claims   1. Formula I {In the formula, Q is [Where R¹, R², R³, R^Four, R^FiveAnd R⁶Independently hydrido and archi Ru, alkoxy, cyano, halo, hydroxy, nitro, amino, alkylamino , Carboxyl, alkoxycarbonyl, formyl, alkylcarbonyl and Selected from haloalkylcarbonyl; R¹And R²Further forms oxo with both May be done; R³And R^FourMay further form oxo with each other; R^FiveAnd And R⁶May further form oxo with each other; d, b and r are each 0 or To 5 (including 1 and 5), and the sum of d + b + r is 0. Is a number from 1 to 5 (including 1 and 5) and R on Q¹~ R⁶At least two Is selected from groups other than hydride or forms groups other than hydride] A cycloalkyl group of choice; R⁷Is hydride, alkyl, halo, halo Selected from alkyl, formyl, carboxyl and alkoxyalkyl; R⁸ Is alkyl, phenyl, phenylalkyl, cycloalkyl and cycloalkyl Selected from rualkyl; m is a number selected from 1 to 4 (including 1 and 4 Mu); A Selected from tylcarbonyl; R¹And R²Even if both form oxo Well; R³And R^FourMay further form oxo with each other; R^FiveAnd R⁶Hasa And may form oxo with each other; d, b and r are each from 0 to 5 ( (Including 1 and 5), the sum of d + b + r is from 0 to 5 A number selected from (including 1 and 5); where R¹~ R⁶At least Two are selected from groups other than hydride or form groups other than hydride; R⁷ Is hydrido, methyl, fluoro, chloro, monofluoromethyl, difluorome Chill, trifluoromethyl, formyl, carboxyl and dimethoxymethyl Selected from; R⁸Is methyl, ethyl, n-propyl, isopropyl, n-butyl , Sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl , Neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobu Cyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropyl Ruethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, From cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl Selected; A is (In the formula, R⁹Is COOH and Is an acidic group selected from) acidic group-substituted pyridinyl-phenyl groups selected from Is a compound represented by or a stereoisomer or tautomer thereof. I Is a pharmaceutically acceptable salt thereof. The compound of claim 1.   3. Formula V [Where R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, Isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, but Lomo, hydroxy, nitro, amino, N-methylamino, N, N-dimethylamino , N-ethylamino, N, N-diethylamino, carboxyl, methoxycarboni Ru, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and And trifluoromethylcarbonyl; R¹And R²And both May form oxo; provided that R on Q¹~ R³At least two species of hydrido Selected from groups other than or forming groups other than hydride: R⁷Is hydrido, Methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, triflu Selected from oromethyl, formyl, carboxyl and dimethoxymethyl; R⁸ Is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, Isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, f Phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl Le, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobu Tylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl Selected from the group consisting of cyclohexyl, cyclohexylmethyl and cyclohexylethyl; A is (R⁹Is COOH and Is an acidic group selected from) acidic group-substituted pyridinyl-phenyl groups selected from Is a compound represented by or a stereoisomer or tautomer thereof. Or a pharmaceutically acceptable salt thereof.   4. Formula V (b) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro Chloro, iodo, bromo. Carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo May be formed; provided that R on Q¹~ R³At least two species other than hydrido A group selected from the group or forming groups other than hydride; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl , Isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl Selected from the group) or its stereoisomers or tautomers or A compound of claim 3 which is a pharmaceutically acceptable salt of.   5. The following groups of compounds: 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-Ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-Isopropyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Me Cyl] -2H-imidazol-2-one; 1- (2-carboxy-5-methylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2,5-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-ethylcyclopentyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-acetyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-oxo-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-methyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro - 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-ethyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,5-diisopropylcyclopentyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-carboxy-5-isopropylcyclopentyl) -4-butyl-1,3-dihi Doro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridini ]] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydr B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-oxo-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[ 6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; and 1- (2,2-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one, its stereoisomers and tautomers, and its pharmaceuticals The compound of "claim 4" selected from the pharmaceutically acceptable salts.   6. Formula VI [Where R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, Isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, but Lomo, hydroxy, nitro, amino, N-methylamino, N, N-dimethylamino , N-ethylamino, N, N-diethylamino, carboxyl, methoxycarboni Ru, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and And trifluoromethylcarbonyl; R¹And R²And both May form oxo; provided that R on Q¹~ R³At least two species of hydrido Selected from groups other than or forming groups other than hydride; R⁷Is hydrido, Methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, triflu Selected from oromethyl, formyl, carboxyl and dimethoxymethyl; R⁸ , Is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl , Isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, Phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopen Chill, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclo Butyl methyl, cyclobutyl ethyl, cyclopentyl methyl, cyclopentyl ethyl Selected from tyl, cyclohexylmethyl and cyclohexylethyl; A is (In the formula, R⁹Is COOH and Is an acidic group selected from) acidic group-substituted pyridinyl-phenyl groups selected from Is a compound represented by or a stereoisomer or tautomer thereof. Or a pharmaceutically acceptable salt thereof.   7. Formula VI (b) (In the formula, R¹, R²And R³Are independently hydrido, methyl, ethyl, n-p Ropil, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, Chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and tho Selected from lifluoromethylcarbonyl; R¹And R²Is both oxo May be formed; provided that R on Q¹~ R³At least two species other than hydrido A group selected from the group or forming groups other than hydride; R⁷Is a hydride; R⁸Is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl , Isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl Selected from the group) or its stereoisomers or tautomers or The compound of claim 6 which is a pharmaceutically acceptable salt thereof.   8. The following groups of compounds: 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-I Midazol-2-one; 1- (2-methyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-ethyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-isopropyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydride B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-oxo-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-methyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-isopropyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydride B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro- 3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Chill] -2H-imidazol-2-one; 1- (2-oxo-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one; 1- (2-methyl-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydr B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydride B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-isopropyl-cyclohexyl) -4-butyl-1,3-di Hydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridi Nyl] methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihi Doro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridini ]] Methyl] -2H-imidazol-2-one; 1- (2-oxo-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydr B-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2,2-diethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one, its stereoisomers and tautomers, and its pharmaceuticals A compound of claim 7 selected from the pharmaceutically acceptable salts.   9.1- (2α, 6α-Dimethyl-1β-cyclohexyl) -4-butyl-1,3-di Hydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridi Nyl] methyl] -2H-imidazol-2-one or a pharmaceutically acceptable salt thereof is there The compound of "claim 8".   10.1- (2,2 Dimethylcyclohexyl-4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methy! ]]-2H-imidazol-2-one or a pharmaceutically acceptable salt thereof. Item 8 ”compound.   11. Selected from the family of compounds according to any of claims 1-10 Therapeutically effective amount of an angiotensin II antagonist compound and pharmaceutically acceptable A pharmaceutical composition comprising a carrier or diluent as defined above.   12. Claims for the manufacture of a medicament for the treatment of cardiovascular disorders or cardiovascular related disorders. Use of the compound according to any one of 1 to 10.   13. The use according to claim 12, wherein the circulatory system disorder is a cardiovascular disorder.   14. The use according to claim 13, wherein the cardiovascular disorder is hypertension.   15. Use according to claim 13, wherein the cardiovascular disorder is congestive heart failure.   16. The use according to claim 12, wherein the cardiovascular-related disorder is glaucoma.

─────────────────────────────────────────────────── --Continued front page (81) Designated countries EP (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OA ( BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES , FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN ( . 72) inventor Manning, Robert E. United States 63,131 Missouri cents Lewis, Ri [continuation of the summary] South Mason Road 1298; R ⁹ COOH and Which is an acidic group selected from the following)] or an angiotensin II antagonist represented by or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt thereof.

Claims (1)

[Claims] 1. Formula I [In the formula, Q is a cycloalkyl group having 3 to about 8 carbon atoms in the ring, and the cycloalkyl group is unsubstituted, at one or more substitutable positions, hydride, alkyl, alkoxy, R may be substituted by one or more groups independently selected from cyano, halo, hydroxy, nitro, amino, alkylamino, carboxyl, alkoxycarbonyl, formyl, oxo, alkylcarbonyl and haloalkylcarbonyl; R ⁷ Is selected from hydride, alkyl, halo, haloalkyl, formyl, carboxyl and alkoxyalkyl; R ⁸ Is selected from alkyl, phenyl, phenylalkyl, cycloalkyl and cycloalkylalkyl; m is a number selected from 1 to 4 (inclusive of 1 and 4); A is (In the formula, R ⁹ Is COOH and Which is an acidic group selected from) and an acidic group-substituted pyridinyl-phenyl group selected from]], its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof. 2. Q group is [Where R ¹ , R ² , R ³ , R ^Four , R ^Five And R ⁶ Are each independently selected from hydride, alkyl, alkoxy, cyano, halo, hydroxy, nitro, amino, alkylamino, carboxyl, alkoxycarbonyl, formyl, alkylcarbonyl and haloalkylcarbonyl; R ¹ And R ² May further form oxo with each other; R ³ And R ^Four May further form oxo with each other; R ^Five And R ⁶ May further form oxo with each other; d, b and r are each a number selected from 0 to 5 (including 1 and 5), and the sum of d + b + r is 0 to 5 (1 and 5). Is included in the number])]. 3. Q group is [Where R ¹ , R ² And R ³ Are each independently selected from hydride, alkyl, alkoxy, cyano, halo, hydroxy, nitro, amino, alkylamino, carboxyl, alkoxycarbonyl, formyl, alkylcarbonyl and haloalkylcarbonyl; R ¹ And R ² May further form oxo with each other]. 4. Formula II [Where R ¹ ~ R ⁶ Are independently hydrido, methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N Selected from -methylamino, N, N-dimethylamino, N-ethylamino, N, N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; R ¹ And R ² May further form oxo with each other; R ³ And R ^Four May further form oxo with each other; R ^Five And R ⁶ May further form oxo with each other; d, b and r are each a number selected from 0 to 5 (including 1 and 5), and the sum of d + b + r is 0 to 5 (1 and 5). Is included); R ⁷ Is selected from hydride, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; R ⁸ Is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclo Selected from propylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; A is (In the formula, R ⁹ Is COOH and Is an acidic group selected from) and is a pyridinyl-phenyl group substituted with an acidic group selected from], its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof. Item 1 ”compound. 5. Formula V [In the formula, R ¹ , R ² And R ³ Are independently hydrido, methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N Selected from -methylamino, N, N-dimethylamino, N-ethylamino, N, N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; R ¹ And R ² May further form oxo with each other; R ⁷ Is selected from hydride, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; R ⁸ Is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl Selected from methyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; A is (R ⁹ Is COOH and Which is an acidic group selected from), which is an acidic group-substituted pyridinyl-phenyl group selected from], its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof. Item 4 "compound. 6. Formula V (b) (In the formula, R ¹ , R ² And R ³ Are each independently selected from hydride, methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; R ¹ And R ² May further form oxo with each other; R ⁷ Is a hydride; R ⁸ Is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) or its stereoisomer or tautomer or The compound of claim 5, which is a pharmaceutically acceptable salt thereof. 7. Compounds of the following group: 1- (2-methylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-ethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] ] -3-Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-propylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole- 5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-isopropylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2-- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one 1- (2-tert-Butylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H -Imidazol-2-one; 1- (2-methoxycyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-hydroxycyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl ] -3-Pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole -5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-ace Lucicopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxocyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole -2-one; 1- (2,4-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2 H-imidazol-2-one; 1- (2-ethyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole- 5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-isopropyl-5-methyl Cyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1 -(2-Carboxy-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-acetyl-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl ] -3-Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxo-5-methylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- ( 1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-methyl- 5-Ethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2- ON; 1- (2,5-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-isopropyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl ) Phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2 -(1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 2-Acetyl-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H- Imidazol-2-one; 1- (2-oxo-5-ethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl]- 3-Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-methyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H- Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-ethyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazo Lu-2-one; 1- (2,5-diisopropylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3- Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-carboxy-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole- 5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-acetyl-5-isopropylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxo-5-isopropylcyclopentyl) -4-butyl-1, 3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridy ]] Methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole-5- Iyl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; and 1- (2,2-diethylcyclopentyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one, selected from stereoisomers and tautomers thereof and pharmaceutically acceptable salts thereof The compound of "claim 6". 8.1-Cyclopentyl-4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2- 8. The compound according to claim 7, which is on or a pharmaceutically acceptable salt thereof. Formula VI [Where R ¹ , R ² And R ³ Are independently hydrido, methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N Selected from -methylamino, N, N-dimethylamino, N-ethylamino, N, N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; R ¹ And R ² May further form oxo with each other; R ⁷ Is selected from hydride, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; R ⁸ Is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclo Selected from propylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; A is (In the formula, R ⁹ Is COOH and Is an acidic group selected from) and is a pyridinyl-phenyl group substituted with an acidic group selected from], its stereoisomer or tautomer, or a pharmaceutically acceptable salt thereof. Item 4 "compound. 10. Formula VI (b) (In the formula, R ¹ , R ² And R ³ Are each independently selected from hydride, methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; R ¹ And R ² May further form oxo with each other; R ⁷ Is a hydride; R ⁸ Is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl, or its stereoisomer or tautomer or The compound of claim 9 which is a pharmaceutically acceptable salt thereof. 11. Compounds of the following group: 1- (2-methylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-ethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] ] -3-Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-propylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole- 5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-isopropylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2-- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one 1- (2-Tert-butylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H -Imidazol-2-one; 1- (2-methoxycyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl ] Methyl] -2H-imidazol-2-one; 1- (2-hydroxycyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] ] -3-Pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole -5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-ace L-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole -2-one; 1- (2-methyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl]- 3-Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H -Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-isopropyl-6-me (Cyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one 1- (2-carboxy-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole-5 -Yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxo-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2- Tyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole -2-one; 1- (2-isopropyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl]- 3-Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H -Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3 -[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole- -One; 1- (2-oxo-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3- Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-methyl-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole -5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one: 1- (2-carboxy-6-isopropyl-cyclohexyl) -4-butyl -1,3-Dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Cyl] -2H-imidazol-2-one; 1- (2-acetyl-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole-5 -Yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxo-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3- Dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2,2-diethylcyclohexyl)- 4-Butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pi] The compound of "claim 10" selected from ridinyl] methyl] -2H-imidazol-2-one, its stereoisomers and tautomers and its pharmaceutically acceptable salts. 12.1-Cyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole-2 -The compound of claim 11 which is on or a pharmaceutically acceptable salt thereof. 13.1- (2α, 6α-1β-Cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one or a pharmaceutically acceptable salt thereof, The compound according to claim 11. 14. 1- (2,2 Dimethylcyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H 15. The compound of "claim 11" which is imidazol-2-one or a pharmaceutically acceptable salt thereof. [Where R ¹ , R ² And R ³ Are independently hydrido, methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N Selected from -methylamino, N, N-dimethylamino, N-ethylamino, N, N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; R ¹ And R ² May further form oxo with each other; R ⁷ Is selected from hydride, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; R ⁸ Is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl Selected from methyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; A is (In the formula, R ⁹ Is COOH and Is an acidic group selected from) and is a pyridinyl-phenyl group substituted with an acidic group selected from], or a stereoisomer or tautomer thereof, or a family of pharmaceutically acceptable salts thereof A pharmaceutical composition comprising a therapeutically effective amount of a selected angiotensin II antagonist compound and a pharmaceutically acceptable carrier or diluent. 16. The antagonist compound has the formula VI (b) (In the formula, R ¹ , R ² And R ³ Are each independently selected from hydride, methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; R ¹ And R ² May further form oxo with each other; R ⁷ Is a hydride; R ⁸ Is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl) or its stereoisomer or tautomer, Or the composition according to claim 15, which is a pharmaceutically acceptable salt thereof. 17． Antagonist compounds are compounds of the following group: 1- (2-methylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl]- 3-Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-ethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole-5- Iyl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-propylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H -Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-isopropylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 -Imidazol-2-one; 1- (2-tert-butylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3 -Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-methoxycyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl ) Phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-hydroxycyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H- Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2 H-imidazol-2-one; 1- (2-carboxycyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole- 2-one; 1- (2-acetylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3 -Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-methyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H- Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3- [[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-Isopropyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 2H-imidazol-2-one; 1- (2-carboxy-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) Phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2 -(1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxo-6-methyl-cyclohexyl) -4-butyl-1,3- Dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazo 1- (2-methyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] ] -3-Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-ethyl-cyclohexyl) -4-methyl-1,3-dihydro-3-[[6- [2-- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-isopropyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-ethyl-cyclohexyl) -4-Butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl -2H-imidazol-2-one; 1- (2-acetyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl ) Phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxo-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-methyl-6-isopropyl-cyclohexyl) -4-butyl-1,3 -Dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-isopropyl- Cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3- Lydinyl] methyl] -2H-imidazol-2-one; 1- (2-isopropyl-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole -5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-isopropyl-cyclohexyl) -4-butyl -1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxo- 6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- ( H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3- [ [6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2,2-diethylcyclohexyl) -4-butyl-1 , 3-Dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one, its stereoisomers and tautomerism A composition according to claim 16 selected from the body, and pharmaceutically acceptable salts thereof. 18. The antagonist compound is 1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole-2. -The composition of claim 17 which is an on or a pharmaceutically acceptable salt thereof. 19. The antagonist compound is 1- (2α, 6α-1β-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] The composition according to claim 17, which is methyl] -2H-imidazol-2-one or a pharmaceutically acceptable salt thereof. 20. The antagonist compound is 1- (2,2 dimethylcyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl]- 21. The composition of claim 17 which is 2H-imidazol-2-one or a pharmaceutically acceptable salt thereof.21. Formula VI [Where R ¹ , R ² And R ³ Are independently hydrido, methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, cyano, fluoro, chloro, iodo, bromo, hydroxy, nitro, amino, N Selected from -methylamino, N, N-dimethylamino, N-ethylamino, N, N-diethylamino, carboxyl, methoxycarbonyl, ethoxycarbonyl, formyl, methylcarbonyl, ethylcarbonyl and trifluoromethylcarbonyl; R ¹ And R ² May further form oxo with each other; R ⁷ Is selected from hydride, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; R ⁸ Is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl Selected from methyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl: A is (In the formula, R ⁹ Is COOH and Which is an acidic group selected from) and which is an acidic group-substituted pyridinyl-phenyl group selected from]], a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof. A therapeutic method for the treatment of a circulatory system disorder or a circulatory system-related disorder, which comprises administering an effective amount to a patient at risk of developing a circulatory system disorder or a circulatory system-related disorder. 22. The active compound has the formula VI (b) (In the formula, R ¹ , R ² And R ³ Are each independently selected from hydride, methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxy, methoxy, fluoro, chloro, iodo, bromo, carboxyl, formyl, methylcarbonyl and trifluoromethylcarbonyl; R ¹ And R ² May further form oxo with each other; R ⁷ Is a hydride; R ⁸ Is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and neopentyl, its stereoisomer or tautomer, Or the method of claim 21, which is a pharmaceutically acceptable salt thereof. 23. The compounds are of the following group: 1- (2-methylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3 -Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-ethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl ) Phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-propylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H- Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-isopropylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [ 2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole- 2-one; 1- (2-tert-butylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] Methyl] -2H-imidazol-2-one; 1- (2-methoxycyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-hydroxycyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole-5 -Yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-carboxycyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2-- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one: 1- ( 2-Acetylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2- On; 1- (2-oxocyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H -Imidazol-2-one; 1- (2-methyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl ] -3-Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-isopro L-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole -2-one; 1- (2-carboxy-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl]- 3-Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H -Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxo-6-methyl-cyclohexyl) -4-butyl-1,3-dihydro-3 -[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-Methyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one; 1- (2-Ethyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole-5- Iyl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-isopropyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-ethyl-cyclohexyl) -4-butyl-1, 3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazole 1- (2-acetyl-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] ] -3-Pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxo-6-ethyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-methyl-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydro -3-[[6- [2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-ethyl-6-isopropyl-cyclohexyl) -4-Butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] me Cyl] -2H-imidazol-2-one; 1- (2-isopropyl-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazole-5 -Yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-carboxy-6-isopropyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-acetyl-6-isopropyl-cyclohexyl) -4-butyl-1 , 3-Dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2-oxo-6- Isopropyl-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazo Lu-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; 1- (2,2-dimethylcyclohexyl) -4-butyl-1,3-dihydro-3-[[6 -[2- (1H-Tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one; and 1- (2,2-diethylcyclohexyl) -4-butyl-1, 3-Dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2-one compounds, their stereoisomers and tautomers The method according to claim 22, which is selected from the sex forms and pharmaceutically acceptable salts thereof. 24. The compound was 1-cyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H-imidazol-2- The method according to claim 23, which is on or a pharmaceutically acceptable salt thereof. 25. The compound was 1- (2α, 6α-1β-cyclohexyl) -4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl ] -2H-Imidazol-2-one or a pharmaceutically acceptable salt thereof, The method according to claim 23. 26. The compound was 1- (2,2 dimethylcyclohexyl-4-butyl-1,3-dihydro-3-[[6- [2- (1H-tetrazol-5-yl) phenyl] -3-pyridinyl] methyl] -2H 27. The method according to claim 23, which is -imidazol-2-one or a pharmaceutically acceptable salt thereof 27. The method according to claim 21, wherein the circulatory system disorder is cardiovascular system disorder 28. Cardiovascular system The vascular disorder is hypertension, the method of claim 27. 29. The cardiovascular disorder is congestive heart failure, the method of claim 27, 30. The cardiovascular disorder is glaucoma. 21 ”method.